var title_f31_6_31840="Rocking bed";
var content_f31_6_31840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rocking bed",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rocking bed shown in head down position. When the bed rocks to a 27 degree foot down position, the diaphragm slides toward the feet, assisting inhalation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31840=[""].join("\n");
var outline_f31_6_31840=null;
var title_f31_6_31841="How to use a peak flow meter";
var content_f31_6_31841=[" <h1 id=\"patTopicTitle\">",
"  Patient information: How to use a peak flow meter (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?31/6/31841/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31841/contributors\" id=\"au7150\">",
"       William Bailey, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31841/contributors\" id=\"au715\">",
"       Lynn B Gerald, PhD, MSPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?31/6/31841/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31841/contributors\" id=\"se5257\">",
"       Peter J Barnes, DM, DSc, FRCP, FRS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?31/6/31841/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31841/contributors\" id=\"de1810\">",
"       Helen Hollingsworth, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?31/6/31841?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PEAK FLOW METER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The management of asthma relies on a patient's ability to monitor their asthma regularly. Self-monitoring includes assessing the frequency and severity of symptoms (such as wheezing and shortness of breath) and measurement of lung function with a peak flow meter.",
"    </p>",
"    <p>",
"     Peak flow meters measure your peak expiratory flow rate (PEFR), a number that correlates with how open the lung's airways are; as asthma worsens and the airways narrow, the PEFR decreases. Monitoring can help you and your healthcare provider determine the most appropriate asthma treatment plan.",
"    </p>",
"    <p>",
"     A number of articles about asthma are available. For children, (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"      \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"      \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     For adults, (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=see_link\">",
"      \"Patient information: Asthma and pregnancy (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ASTHMA MONITORING RECOMMENDATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Experts recommend that people with moderate to severe persistent asthma have a peak flow meter at home and know how to use it [",
"     <a class=\"abstract\" href=\"UTD.htm?31/6/31841/abstract/1\">",
"      1",
"     </a>",
"     ]. A peak flow meter is small, inexpensive, and easy for most patients to use.",
"    </p>",
"    <p>",
"     The National Asthma Education and Prevention Program (NAEPP) recommends that patients use a peak flow meter to:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Regularly monitor lung function and response to treatment over the short- and long-term",
"      </li>",
"      <li>",
"       Determine the severity of an asthma attack",
"      </li>",
"      <li>",
"       Assess response to treatment during an attack",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     You should use an asthma diary to record your daily peak flow meter readings, exposure to potential asthma triggers, asthma medication use, and asthma symptoms (",
"     <a class=\"graphic graphic_form graphicRef68404 \" href=\"UTD.htm?4/13/4305\">",
"      form 1",
"     </a>",
"     and",
"     <a class=\"graphic graphic_form graphicRef76505 \" href=\"UTD.htm?9/35/9776\">",
"      form 2",
"     </a>",
"     ). This can help to show a cause-and-effect relationship between exposure to triggers and decreases in peak flow. You can review the asthma diary with a healthcare provider to make decisions about asthma treatment.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      HOW TO USE A PEAK FLOW METER",
"     </span>",
"    </p>",
"    <p>",
"     Peak flow monitoring should be performed on a regular basis, even when asthma symptoms are not present. Peak flow should also be checked if symptoms of coughing, wheezing, or shortness of breath develop. You should demonstrate how to use a peak flow meter with your healthcare provider to verify that your technique is accurate.",
"    </p>",
"    <p>",
"     Different brands of peak flow meters have unique features; however, these general instructions can be adapted to an individual's peak flow meter.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Getting the best readings",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several steps are important to make sure the peak flow meter records an accurate value:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The peak flow meter should read zero or its lowest reading when not in use.",
"      </li>",
"      <li>",
"       Use the peak flow meter while standing up straight.",
"      </li>",
"      <li>",
"       Take in as deep a breath as possible.",
"      </li>",
"      <li>",
"       Place the peak flow meter in the mouth, with the tongue under the mouthpiece.",
"      </li>",
"      <li>",
"       Close the lips tightly around the mouthpiece.",
"      </li>",
"      <li>",
"       Blow out as hard and fast as possible; do not throw the head forward while blowing out.",
"      </li>",
"      <li>",
"       Breathe a few normal breaths and then repeat the process two more times. Write down the highest number obtained. Do not average the numbers.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     IMPORTANT: Repeat the test if your tongue partially blocks the mouthpiece or if you cough or spit during the test. Most peak flow meters need to be cleaned periodically; cleaning instructions should be available when the unit is purchased.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Establishing a baseline measurement",
"     </span>",
"     &nbsp;&mdash;&nbsp;Unlike a blood pressure reading or a cholesterol test, there is no peak flow measurement that is normal for everyone. For this reason, it is important to determine what peak flow value is normal for you.",
"    </p>",
"    <p>",
"     To determine your",
"     <strong>",
"      normal",
"     </strong>",
"     peak flow measurement, you should measure your peak flow when you have no asthma symptoms. Perform three measurements with the same peak flow meter two to four times daily for two to three weeks.",
"    </p>",
"    <p>",
"     You should note the highest peak flow measurement achieved; this is the &ldquo;personal best.&rdquo; This number is used to determine if future peak flow measurements are normal or low, and is also used to create a normal range (between 80 and 100 percent of the personal best peak flow measurement).",
"    </p>",
"    <p>",
"     Readings below the normal range are a sign of airway narrowing in the lungs. A low peak flow measurement can occur before asthma symptoms such as wheezing or shortness of breath develop.",
"    </p>",
"    <p>",
"     Remeasure your personal best peak flow value once per year to account for growth (in children) or changes in the disease (in both children and adults). In addition, verify home peak flow measurements with readings taken with equipment in a healthcare provider's office since this equipment is more sensitive. For long term management, most clinicians will recommend peak flow testing once per day, usually in the morning.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      ASTHMA EMERGENCY CARE",
"     </span>",
"    </p>",
"    <p>",
"     If you do not improve or worsen despite treatment, you need emergency medical care. Severe asthma attacks can be fatal if not treated promptly. In most areas of the United States, you can call 911 for emergency medical assistance. Do not attempt to drive to a hospital or clinician's office on your own.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H71\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3051576194\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=see_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3051576256\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=see_link\">",
"      Patient information: Asthma and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"      An overview of asthma management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12789?source=see_link\">",
"      Enhancing patient adherence to asthma therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18154?source=see_link\">",
"      Treatment of intermittent and mild persistent asthma in adolescents and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/\">",
"      www.lungusa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Allergy, Asthma, and Immunology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;",
"     <span class=\"nowrap\">",
"      (file://www.aaaai.org/conditions-and-treatments/asthma.aspx)",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Allergy, Asthma, and Immunology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acaai.org/allergist\">",
"      www.acaai.org/allergist",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?31/6/31841/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?31/6/31841?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31841/abstract/2\">",
"      Caress AL, Luker K, Beaver K, Woodcock A. Adherence to peak flow monitoring. Information provided by meters should be part of self management plan. BMJ 2002; 324:1157; author reply 1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31841/abstract/3\">",
"      Wensley D, Silverman M. Peak flow monitoring for guided self-management in childhood asthma: a randomized controlled trial. Am J Respir Crit Care Med 2004; 170:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31841/abstract/4\">",
"      Tierney WM, Roesner JF, Seshadri R, et al. Assessing symptoms and peak expiratory flow rate as predictors of asthma exacerbations. J Gen Intern Med 2004; 19:237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_6_31841=[""].join("\n");
var outline_f31_6_31841=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PEAK FLOW METER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ASTHMA MONITORING RECOMMENDATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           HOW TO USE A PEAK FLOW METER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           ASTHMA EMERGENCY CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FORMS",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"UTD.htm?4/13/4305\" title=\"form 1\">",
"           Asthma monitoring form PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_form\" href=\"UTD.htm?9/35/9776\" title=\"form 2\">",
"           Asthma peak flow daily diary II",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_6_31842="Patient information: Chronic pulmonary aspergillosis (The Basics)";
var content_f31_6_31842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/31/41457\">",
"         Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/59/5043\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/0/43011\">",
"         Patient information: Cough in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/43/22195\">",
"         Patient information: Coughing up blood (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/14/20705\">",
"         Patient information: Sarcoidosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/57/25489\">",
"         Patient information: Tuberculosis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/13/1236\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/35/39475\">",
"         Patient information: Tuberculosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chronic pulmonary aspergillosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chronic-pulmonary-aspergillosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H95544092\">",
"      <span class=\"h1\">",
"       What is chronic pulmonary aspergillosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chronic pulmonary aspergillosis is a lung disease that causes weight loss, cough, and other symptoms. It lasts for longer than 3 months. It is caused by infection with a fungus called &ldquo;aspergillus.&rdquo; &nbsp;",
"     </p>",
"     <p>",
"      Chronic pulmonary aspergillosis happens in people who already have lung damage or disease, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Tuberculosis &ndash; This is a lung infection caused by a certain type of bacteria.",
"       </li>",
"       <li>",
"        Chronic obstructive pulmonary disease, also called &ldquo;COPD&rdquo; &ndash; This is a lung condition that makes it hard to breathe.",
"       </li>",
"       <li>",
"        Sarcoidosis &ndash; This disease causes clusters of abnormal tissue called &ldquo;granulomas&rdquo; to form in the body. It can cause scar tissue to form in the lungs. &nbsp;",
"       </li>",
"       <li>",
"        Allergic bronchopulmonary aspergillosis &ndash; This is an allergic reaction to the aspergillus fungus.",
"       </li>",
"       <li>",
"        Lung cancer treatment in the past.",
"       </li>",
"       <li>",
"        Pneumothorax in the past &ndash; &ldquo;Pneumothorax&rdquo; is the medical term for a collapsed lung.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some other conditions raise your risk for chronic pulmonary aspergillosis. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Diabetes",
"       </li>",
"       <li>",
"        Alcoholism",
"       </li>",
"       <li>",
"        Taking steroid medicines &ndash; These medicines make it harder for the immune system to work correctly. They are not the same as the steroids athletes take to build muscle.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95544107\">",
"      <span class=\"h1\">",
"       What are the symptoms of chronic pulmonary aspergillosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Losing weight without trying",
"       </li>",
"       <li>",
"        Coughing &ndash; The cough often brings up mucus. Some people cough up blood. A mild cough is the only symptom some people have.",
"       </li>",
"       <li>",
"        Feeling short of breath &ndash; You might feel like you cannot get enough air or have to work harder than normal to breathe.",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Chest pain &ndash; This might be a sharp, stabbing pain that gets worse when you breathe in.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people have a fever or get hot and sweaty at night.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95544122\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse right away if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have a cough and have lost weight without trying.",
"       </li>",
"       <li>",
"        You cough up blood.",
"       </li>",
"       <li>",
"        You have sharp, stabbing chest pain that gets worse when you breathe in. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95544137\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes.",
"      <strong>",
"      </strong>",
"      The doctor or nurse will do an exam and learn about your symptoms. You will also have some or all of these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chest X-ray",
"       </li>",
"       <li>",
"        CT scan of the chest &ndash; This is an imaging test that uses a special X-ray to create pictures of the inside of the body. It can show more detail than a regular X-ray.",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Breathing tests &ndash; For these tests, you breathe hard into a tube. The tests show how well your lungs are working.",
"       </li>",
"       <li>",
"        Tests on a sample of mucus that you cough up",
"       </li>",
"       <li>",
"        Bronchoscopy &ndash; This is a procedure in which a doctor uses a thin tube (called a &ldquo;bronchoscope&rdquo;) to look inside your lungs and get a sample of fluid. You might have this test if other tests do not show whether you have chronic pulmonary aspergillosis for sure.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95544154\">",
"      <span class=\"h1\">",
"       How is chronic pulmonary aspergillosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your situation, including any other lung problems you have. Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines - These can kill the fungus that causes aspergillosis. You might take pills by mouth or get medicine through an &ldquo;IV,&rdquo; a thin tube that goes into a vein.",
"       </li>",
"       <li>",
"        A procedure called &ldquo;embolization&rdquo; &ndash; In this procedure, a doctor blocks blood vessels that are leaking into the lung. To do this, the doctor puts a thin tube into a blood vessel in your leg. Next, he or she moves the tube up to the area that is bleeding. Then the doctor uses the tube to put something in the blood vessel to block it, such as tiny plastic beads. You might have this procedure if you are coughing up a lot of blood.",
"       </li>",
"       <li>",
"        Surgery &ndash; Aspergillosis sometimes causes a ball of fungus, mucus, and cells to form in the lung. Doctors call this an &ldquo;aspergilloma&rdquo; or &ldquo;fungus ball.&rdquo; If it causes symptoms, such as coughing up blood, doctors might do surgery to take it out. But if a fungus ball does not cause symptoms, you might not need treatment right away. Your doctor can do regular exams and X-rays to check on it and treat it if it gets worse. &nbsp;",
"       </li>",
"       <li>",
"        Oxygen &ndash; If you have trouble breathing, you might need extra oxygen. You can get extra oxygen through a tube that goes to your nose or a mask you wear.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have surgery or embolization, you will probably also take medicine to kill the fungus. This can help keep it from spreading.",
"     </p>",
"     <p>",
"      Many people who have chronic pulmonary aspergillosis need to take medicine for a long time, sometimes for life. These people need regular exams, blood tests, and chest X-rays to check how well the medicine is working. If it is not working well, they might need to switch treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H95544169\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/31/41457?source=see_link\">",
"       Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"       Patient information: Cough in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=see_link\">",
"       Patient information: Coughing up blood (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=see_link\">",
"       Patient information: Sarcoidosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/57/25489?source=see_link\">",
"       Patient information: Tuberculosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"       Patient information: Tuberculosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?31/6/31842?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83431 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31842=[""].join("\n");
var outline_f31_6_31842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95544092\">",
"      What is chronic pulmonary aspergillosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95544107\">",
"      What are the symptoms of chronic pulmonary aspergillosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95544122\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95544137\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95544154\">",
"      How is chronic pulmonary aspergillosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95544169\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/31/41457?source=related_link\">",
"      Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=related_link\">",
"      Patient information: Coughing up blood (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=related_link\">",
"      Patient information: Sarcoidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=related_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/57/25489?source=related_link\">",
"      Patient information: Tuberculosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_6_31843="Collagenase (topical): Patient drug information";
var content_f31_6_31843=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Collagenase (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/11/41138?source=see_link\">",
"     see \"Collagenase (topical): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Santyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13259795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Santyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691571",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to promote healing of skin ulcers and wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691339",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower odor from wounds.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to collagenase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11526 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31843=[""].join("\n");
var outline_f31_6_31843=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154628\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13259795\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031518\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031517\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031522\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031523\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031525\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031520\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031521\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031526\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031527\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/29/5588?source=related_link\">",
"      Collagenase (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/53/6996?source=related_link\">",
"      Collagenase (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/11/41138?source=related_link\">",
"      Collagenase (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_6_31844="Carbidopa-levodopa: Patient drug information";
var content_f31_6_31844=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carbidopa-levodopa: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     see \"Carbidopa-levodopa: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Parcopa&reg;;",
"     </li>",
"     <li>",
"      Sinemet&reg;;",
"     </li>",
"     <li>",
"      Sinemet&reg; CR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Levocarb&reg;;",
"     </li>",
"     <li>",
"      Apo-Levocarb&reg; CR;",
"     </li>",
"     <li>",
"      Dom-Levo-Carbidopa;",
"     </li>",
"     <li>",
"      Duodopa&trade;;",
"     </li>",
"     <li>",
"      Levocarb CR;",
"     </li>",
"     <li>",
"      Nu-Levocarb;",
"     </li>",
"     <li>",
"      PRO-Levocarb;",
"     </li>",
"     <li>",
"      Sinemet&reg;;",
"     </li>",
"     <li>",
"      Sinemet&reg; CR;",
"     </li>",
"     <li>",
"      Teva-Levocarbidopa",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat restless leg syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702381",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to levodopa, carbidopa, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma, melanoma, or skin spots.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid a high protein diet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"       Place on your tongue and let it melt. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole or as a half. Do not chew or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696477",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take long-acting products more often than every 6 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10801 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31844=[""].join("\n");
var outline_f31_6_31844=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187993\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187994\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023212\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023211\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023216\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023217\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023219\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023214\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023215\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023220\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023221\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=related_link\">",
"      Carbidopa-levodopa: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_6_31845="Multiple neurofibromas";
var content_f31_6_31845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple neurofibromas in an adult patient with neurofibromatosis type 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple papules and nodules consistent with neurofibromas are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31845=[""].join("\n");
var outline_f31_6_31845=null;
var title_f31_6_31846="Anatomic relationship of colon to surrounding structures";
var content_f31_6_31846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Anatomic relationship of colon to surrounding structures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the relationship of the large intestine to the overlying and underlying organs and vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31846=[""].join("\n");
var outline_f31_6_31846=null;
var title_f31_6_31847="Magnesium hydroxide: Drug information";
var content_f31_6_31847=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium hydroxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/49/19220?source=see_link\">",
"    see \"Magnesium hydroxide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/59/29622?source=see_link\">",
"    see \"Magnesium hydroxide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet&reg; Pedia-Lax&trade; Chewable Tablet [OTC];",
"     </li>",
"     <li>",
"      Little Phillips'&reg; Milk of Magnesia [OTC];",
"     </li>",
"     <li>",
"      Milk of Magnesia [OTC];",
"     </li>",
"     <li>",
"      Milk of Magnesium [OTC];",
"     </li>",
"     <li>",
"      Phillips'&reg; Milk of Magnesia [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antacid;",
"     </li>",
"     <li>",
"      Laxative;",
"     </li>",
"     <li>",
"      Magnesium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antacid:",
"     </b>",
"     OTC labeling: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Liquid:",
"     </i>",
"     Magnesium hydroxide 400 mg/5 mL: 5-15 mL as needed up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tablet:",
"     </i>",
"     Magnesium hydroxide 311 mg/tablet: 2-4 tablets every 4 hours up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Laxative:",
"     </b>",
"     OTC labeling: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Liquid:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Magnesium hydroxide 400 mg/5 mL: 30-60 mL/day once daily at bedtime or in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Magnesium hydroxide 800 mg/5 mL: 15-30 mL/day once daily at bedtime or in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tablet:",
"     </i>",
"     Magnesium hydroxide 311 mg/tablet: 8 tablets/day once daily at bedtime or in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F190925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/59/29622?source=see_link\">",
"      see \"Magnesium hydroxide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antacid:",
"     </b>",
"     OTC labeling: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Liquid:",
"     </i>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tablet:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;12 years: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Laxative:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Liquid:",
"     </i>",
"     Magnesium hydroxide 400 mg/5 mL: 1-3 mL/kg/day; adjust dose to induce daily bowel movement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     OTC labeling:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:6em;text-align:justify;\">",
"     Children &lt;2 years: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 2-5 years: Magnesium hydroxide 400 mg/5 mL: 5-15 mL/day once daily at bedtime or in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Magnesium hydroxide 400 mg/5 mL: 15-30 mL/day once daily at bedtime or in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Magnesium hydroxide 800 mg/5 mL: 7.5-15 mL/day once daily at bedtime or in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tablet:",
"     </i>",
"     OTC labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;3 years: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3-5 years: Magnesium hydroxide 311 mg/tablet: 2 tablets/day once daily at bedtime or in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-11 years: Magnesium hydroxide 311 mg/tablet: 4 tablets/day once daily at bedtime or in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F190921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients in severe renal failure should not receive magnesium due to toxicity from accumulation. Patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute should be monitored by serum magnesium levels.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 400 mg/5 mL (30 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Milk of Magnesia: 400 mg/5 mL (360 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Milk of Magnesia: 400 mg/5 mL (355 mL, 360 mL, 473 mL) [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Milk of Magnesia: 400 mg/5 mL (480 mL) [ethanol free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Milk of Magnesium: 400 mg/5 mL (3.78 L, 473 mL) [contains magnesium 165 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phillips'&reg; Milk of Magnesia: 400 mg/5 mL (120 mL, 360 mL, 780 mL) [contains magnesium 167 mg/5 mL; fresh mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phillips'&reg; Milk of Magnesia: 400 mg/5 mL (120 mL, 360 mL, 780 mL) [contains magnesium 167 mg/5 mL; original flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phillips'&reg; Milk of Magnesia: 400 mg/5 mL (120 mL, 240 mL, 360 mL, 780 mL) [contains magnesium 167 mg/5 mL, sodium 2 mg/5 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [concentrate]: 2400 mg/10 mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Phillips'&reg; Milk of Magnesia: 800 mg/5 mL (120 mL) [contains magnesium 333 mg/5 mL, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Milk of Magnesia: 800 mg/5 mL (100 mL, 400 mL) [contains sodium 20 mg/10 mL, sucrose 0.8 g/10 mL; lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phillips'&reg; Milk of Magnesia: 800 mg/5 mL (240 mL) [contains magnesium 333 mg/5 mL, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Pedia-Lax&trade; Chewable Tablet: 400 mg [contains magnesium 170 mg/tablet; watermelon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phillips'&reg; Milk of Magnesia: 311 mg [mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phillips'&reg; Milk of Magnesia: 311 mg [contains magnesium 130 mg/tablet; mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Liquid",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F190908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liquid doses may be diluted with a small amount of water prior to administration. All doses should be followed by 8 ounces of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of occasional constipation and symptoms of hyperacidity, laxative",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to magnesium hydroxide or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC use: For occasional use only; serious side effects may occur with prolonged use. For use only under the supervision of a healthcare provider in patients with kidney dysfunction, or with a sudden change in bowel habits which persist for &gt;2 weeks. Do not use if abdominal pain, nausea, or vomiting are present. Patients should notify healthcare provider of any sudden change in bowel habits which last &gt;14 days, stomach pain, nausea, or vomiting or if use is needed for &gt;1 week. Not for OTC use in children &lt;2 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: Antacids may enhance the adverse/toxic effect of Misoprostol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Magnesium Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and magnesium hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14081348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama, 1998; Osada, 2002). The American Gastroenterological Association considers the use of magnesium containing antacids to be low risk in pregnancy (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14081349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions (IOM, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9732704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6855871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Pedia-Lax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $5.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Phillips Milk of Magnesia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     311 mg (100): $4.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Phillips Milk of Magnesia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/5 mL (118 mL): $2.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg/5 mL (237 mL): $4.74",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Chlorumagene (FR);",
"     </li>",
"     <li>",
"      Deopens (ZA);",
"     </li>",
"     <li>",
"      Emgesan (FI, SE);",
"     </li>",
"     <li>",
"      Laxasium (ID);",
"     </li>",
"     <li>",
"      Leche De Magnesia (CO, EC, PE);",
"     </li>",
"     <li>",
"      Magnesia san Pelligrino (IT);",
"     </li>",
"     <li>",
"      Marogel (KP);",
"     </li>",
"     <li>",
"      Milk of Magnesia (IL, PL);",
"     </li>",
"     <li>",
"      Milmag (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F190894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes bowel evacuation by causing osmotic retention of fluid which distends the colon with increased peristaltic activity; reacts with hydrochloric acid in stomach to form magnesium chloride",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Laxative: 30 minutes to 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (up to 30% as absorbed magnesium ions); feces (as unabsorbed drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chernow B, Smith J, Rainey TG, et al, &ldquo;Hypomagnesemia: Implications for the Critical Care Specialist,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1982, 10(3):193-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/6/31847/abstract-text/7037303/pubmed\" id=\"7037303\" target=\"_blank\">",
"        7037303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Constipation Guideline Committee, &ldquo;Clinical Practice Guideline. Evaluation and Treatment of Constipation of Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition,&rdquo;",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2006, 43(3):e1-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/6/31847/abstract-text/16954945/pubmed\" id=\"16954945\" target=\"_blank\">",
"        16954945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gams JG, &ldquo;Clinical Significance of Magnesium: A Review,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(3):240-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/6/31847/abstract-text/3552543/pubmed\" id=\"3552543\" target=\"_blank\">",
"        3552543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Idama TO and Lindow SW, \"Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,\"",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1998, 105(3):260-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/6/31847/abstract-text/9532984/pubmed\" id=\"9532984\" target=\"_blank\">",
"        9532984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute of Medicine (IOM),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , National Academy of Sciences, Washington, DC, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/6/31847/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osada H, Watanabe Y, Nishimura Y, et al, \"Profile of Trace Element Concentrations in the Feto-placental Unit in Relation to Fetal Growth,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2002, 81(10):931-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?31/6/31847/abstract-text/12366483/pubmed\" id=\"12366483\" target=\"_blank\">",
"        12366483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9582 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31847=[""].join("\n");
var outline_f31_6_31847=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190917\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190928\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190919\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190925\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190920\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190921\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190904\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190891\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190908\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190907\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190911\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190895\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299634\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221407\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14081348\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14081349\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9732704\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855871\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038670\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190894\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190910\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9582\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9582|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/49/19220?source=related_link\">",
"      Magnesium hydroxide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/59/29622?source=related_link\">",
"      Magnesium hydroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_6_31848="The biology of IgE";
var content_f31_6_31848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The biology of IgE",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/6/31848/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31848/contributors\">",
"     Jeff Stokes, MD, FAAAAI, FACAAI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31848/contributors\">",
"     Thomas B Casale, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/6/31848/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31848/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/6/31848/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31848/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/6/31848/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13745029\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of many allergic diseases involves &ldquo;allergic&rdquo; antibody or immunoglobulin E (IgE) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/1\">",
"     1",
"    </a>",
"    ]. This topic will review the structure, biology, and functions of IgE. A review of the role of IgE in allergic diseases, and more general discussions of immunoglobulin structure and function are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30056?source=see_link\">",
"     \"The relationship between IgE and allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=see_link\">",
"     \"Structure of immunoglobulins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745037\">",
"    <span class=\"h1\">",
"     ROLES OF IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE is important in defense against parasitic diseases, especially those caused by helminthes and some protozoa [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, due in part to the redundancy of the immune system, low or absent levels of IgE do not predispose people to severe parasitic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/4\">",
"     4",
"    </a>",
"    ]. IgE is",
"    <strong>",
"     not",
"    </strong>",
"    believed to play an important role in defense against bacterial infections, since it does not activate complement or participate in opsonization [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/5\">",
"     5",
"    </a>",
"    ]. IgE plays a key role in the pathogenesis of allergic diseases, especially mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation, and in antigen presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745045\">",
"    <span class=\"h1\">",
"     STRUCTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin E is one of five isotypes of human immunoglobulins, IgG, IgA, IgM, IgD, and IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    All immunoglobulins are composed of two light chains and two identical heavy chains (",
"    <a class=\"graphic graphic_figure graphicRef83423 \" href=\"UTD.htm?3/41/3733\">",
"     figure 1",
"    </a>",
"    ). The heavy chain differentiates the various immunoglobulin isotypes. The heavy chain in IgE is &epsilon; (epsilon). IgE is a monomer, and consists of four constant regions, in contrast to other immunoglobulins that contain only three constant regions. Due to this extra region, the weight of IgE is 190 kDa compared to 150 kDa for IgG.",
"   </p>",
"   <p>",
"    The C&epsilon;2 constant domain is unique to IgE, while the C&epsilon;3 region binds to the low and high affinity IgE receptor. Of note, the anti-IgE monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    also binds to the C&epsilon;3 region, so the binding of omalizumab to IgE decreases the amount of &ldquo;free&rdquo; IgE available for binding to IgE receptor-bearing cells including mast cells and basophils (",
"    <a class=\"graphic graphic_figure graphicRef83423 \" href=\"UTD.htm?3/41/3733\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link\">",
"     \"Anti-IgE therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745053\">",
"    <span class=\"h1\">",
"     SYNTHESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies are produced by plasma cells. These cells are programmed to make IgM by default, but undergo &ldquo;isotype switching&rdquo; to produce IgE with the same antigenic specificity under specific conditions. This process requires cell surface interactions between B and T cells, as well as soluble factors from various cell types [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/1,8-10\">",
"     1,8-10",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    During isotype switching, genomic DNA is spliced and rejoined in class switch recombination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link&amp;anchor=H17#H17\">",
"     \"The humoral immune response\", section on 'Cellular events in b cell activation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    B cell isotype switching requires two signals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first signal involves the soluble factors interleukin-4 (IL-4) and 13 (IL-13) released by Th2 cells, mast cells, and basophils. Interaction of these cytokines with their respective receptors on B cells activates transcription at the specific &epsilon; germline locus via signal transducer and activator of transcription (STAT) 6.",
"     </li>",
"     <li>",
"      The second signal is the interaction between the B cell CD40 and T cell CD40 ligand (CD154). The second signal results in DNA class switch recombination and IgE expression triggered by nuclear factor &kappa;B (NF&kappa;B). STAT6 and NF&kappa;B synergize to activate B cell activator protein (BSAP), promoting production of IgE. The removal of the unwanted constant regions by splicing and rejoining of the DNA requires AID (activation-induced cytidine deaminase) and UNG (uracil DNA glycosylase). Accessory molecules that amplify IgE production include",
"      <span class=\"nowrap\">",
"       CD28/CD80-CD86",
"      </span>",
"      interactions. In addition there are negative signals that reduce IgE production: ID2 (inhibitor of DNA binding 2) binds to E-box; BCL-6 (B cell lymphoma 6) competes with STAT6; and SOCS-1 (suppressor of cytokine signaling 1) also works on STAT-6. Interferon gamma can also inhibit IgE production via STAT1-mediated activation of SOCS1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    B cell isotype switching to produce antigen-specific IgE occurs primarily in mucosal lymphoid tissues, with the greatest amounts of antigen-specific IgE production in tonsils and adenoids, although some also occurs in peripheral tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The newly formed IgE then diffuses through the tissues and into the circulation (",
"    <a class=\"graphic graphic_figure graphicRef55328 \" href=\"UTD.htm?41/30/42469\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1397010\">",
"    <span class=\"h2\">",
"     Localized IgE production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antigen-specific IgE production occurs locally within the bronchial and nasal mucosa, in addition to the lymphoid tissues and bone marrow, even in patients who are considered nonatopic by skin testing and laboratory tests [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. One study suggested that more than 99 percent of circulating allergen-specific IgE was produced within the tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/12\">",
"     12",
"    </a>",
"    ]. This phenomenon of local IgE production is termed entopy and may underlie some cases of chronic nonallergic rhinitis and severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264545938\">",
"    <span class=\"h2\">",
"     Regulation of synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic predisposition to develop allergic disease, or atopy, is a complex trait that is not fully understood. Total serum IgE levels and regulation of serum IgE production are strongly influenced by genetic factors. Less is known about other genetic factors important for the development of allergic disease. Genome-wide association studies have identified several loci that may be important for IgE regulation, including loci in the gene encoding the alpha chain of the high affinity receptor for IgE (FC&epsilon;RIa), STAT6, and in the gene",
"    <span class=\"nowrap\">",
"     RAD50/IL-13",
"    </span>",
"    cluster [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745061\">",
"    <span class=\"h1\">",
"     IgE RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE functions through its high and low affinity receptors on mast cells, basophils and other cells leading to degranulation of mast cells and basophils and antigen presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/1,5,11,23\">",
"     1,5,11,23",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Expression of both receptors is enhanced by IgE binding, so circulating IgE levels are positively correlated with receptor levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745069\">",
"    <span class=\"h2\">",
"     High affinity receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high affinity receptor for IgE is Fc&epsilon;RI. IgE binds to the &alpha; chain [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/5\">",
"     5",
"    </a>",
"    ]. Fc&epsilon;RI exists in two forms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A tetrameric form (&alpha;&beta;&gamma;",
"      <sub>",
"       2",
"      </sub>",
"      ) of Fc&epsilon;RI is expressed on mast cells and basophils. In the nonactivated state, these cells are coated with Fc&epsilon;RI receptors bound to various antigen-specific IgE molecules. If that multivalent antigen (allergen) enters the cell&rsquo;s environment, it binds to the IgE, causing the Fc&epsilon;RI receptors to cluster on the cell surface and become cross-linked. Cross-linking leads to activation of the cell and release of preformed mediators from cytoplasmic granules (eg, histamine), transcription and release of cytokines, and synthesis of leukotrienes and prostaglandins [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/9\">",
"       9",
"      </a>",
"      ]. The strength of the activation signal depends upon the polyvalency of the allergen (ie, number of binding sites for IgE) and the affinity of the IgE for the allergen. The inflammatory mediators released by mast cells and basophils include histamine, tryptases, and tumor necrosis factor &alpha;, as well as leukotrienes and prostaglandins (LTC4 and PGD2, respectively). These mediators are responsible for the signs and symptoms of immediate hypersensitivity. In addition, production of the Th2 cytokines IL-4, IL-5, and IL-13 initiates late phase inflammation and promotes more IgE production. These mechanisms underlie the clinical manifestations of allergic diseases, such as allergic rhinitis and conjunctivitis, allergic asthma, food allergy, and anaphylaxis. The mediators released by mast cells are reviewed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=see_link\">",
"       \"Mast cell derived mediators\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A trimeric form of Fc&epsilon;RI (&alpha;&gamma;",
"      <sub>",
"       2",
"      </sub>",
"      ) is expressed on Langerhans cells, dendritic cells, and monocytes. It is important for antigen presentation. In humans, it is theorized that Fc&epsilon;RI on antigen-presenting cells permits the transport of antigens captured by IgE in the tissues into peripheral lymph nodes to initiate immune responses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745077\">",
"    <span class=\"h2\">",
"     Low affinity receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low affinity IgE receptor, Fc&epsilon;RII (CD23), is present on a variety of cells [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/10\">",
"     10",
"    </a>",
"    ]. The constitutively expressed form, CD23a, is present only on B cells while the inducible form, CD23b, is present on B-cells, T-cells, dendritic cells, monocytes, macrophages, neutrophils, eosinophils, intestinal epithelial cells, and platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functions include regulation of IgE synthesis (binding of IgE to B cell CD23 inhibits IgE synthesis), antigen capture and presentation, and growth and differentiation of B cells. Epithelial cell CD23 transports IgE-allergen complexes from the lumen to the mucosa to interact with mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/10\">",
"     10",
"    </a>",
"    ]. CD23 can be shed from the cell membrane (sCD23) by endogenous proteases, creating a soluble form that may be important for upregulation of IgE synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745085\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF IgE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745093\">",
"    <span class=\"h2\">",
"     Total IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total IgE levels are frequently measured by a sandwich-type assay. In this method, anti-IgE antibody is bound to a solid support [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/28\">",
"     28",
"    </a>",
"    ]. Serum from a patient is added, and then unbound protein is washed away. A second, labeled anti-IgE antibody is added, and the amount bound to the patient&rsquo;s IgE is measured. Total serum IgE levels are reported as international units or nanograms per milliliter (1",
"    <span class=\"nowrap\">",
"     IU/ml",
"    </span>",
"    = 2.44",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745101\">",
"    <span class=\"h2\">",
"     Allergen-specific IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first commercial assay for allergen-specific IgE was the RadioAllergoSorbent Test (RAST) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The bound allergen-specific IgE was detected with radioiodinated polyclonal antihuman IgE and quantified with a gamma counter. The term RAST is still frequently used to refer to in vitro assays for allergen-specific IgE, although modern methods use enzymes instead of radionucleotides. A number of other technical advances in assay technology have dramatically improved the sensitivity and specificity of allergen-specific IgE measurements. The terms &ldquo;",
"    <em>",
"     in vitro",
"    </em>",
"    IgE antibody assay&rdquo; or &ldquo;allergen-specific IgE immunoassay&rdquo; more accurately characterize the three current IgE antibody assays clinically available in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The HYTEC-288 is a colorimetric assay using a paper disc solid-phase support.",
"     </li>",
"     <li>",
"      The ImmunoCAP is a fluoroimmunoassay with a cellulose sponge solid-phase matrix.",
"     </li>",
"     <li>",
"      The Immulite chemiluminescent assay has a biotinylated-allergen and avidin particle solid-phase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The three systems use extracts from different sources immobilized as the antigen capture allergosorbent, and thus the results are not interchangeable. These tests quantify allergen-specific IgE, which may or may not correlate with allergic disease or specific symptoms. The use of immunoassays in the diagnosis of allergic disease is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of in vitro allergy tests\", section on 'Immunoassays'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lower limit of detection for allergen-specific IgE is lower than that for total IgE. Most labs have a lower limit of approximately 0.1 to 0.35",
"    <span class=\"nowrap\">",
"     IU/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15831806\">",
"    <span class=\"h2\">",
"     Affect of omalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    , the monoclonal anti-IgE antibody, binds to free serum IgE and forms immune complexes that increase circulating total IgE levels five- to sixfold. The accuracy of most in vitro assays for total serum IgE is compromised by the presence of omalizumab, although one commercially-available system (Pharmacia ImmunoCAP) retains reasonable accuracy for both total and allergen-specific IgE measurements in the presence of omalizumab [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/31\">",
"     31",
"    </a>",
"    ]. Note that none of the clinically used total serum IgE assays measure &ldquo;free&rdquo; IgE in the presence of omalizumab. Rather, it is the level of total IgE (free and omalizumab-bound) that is assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745109\">",
"    <span class=\"h1\">",
"     IgE LEVELS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745117\">",
"    <span class=\"h2\">",
"     Normal levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE has the lowest serum concentration of all the immunoglobulins, ~150",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    compared to 10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    for IgG, or 66,000-fold less [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/5,23\">",
"     5,23",
"    </a>",
"    ]. Normal serum levels range from approximately 0 to 100",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    (sometimes expressed in",
"    <span class=\"nowrap\">",
"     kU/L,",
"    </span>",
"    depending upon the laboratory). IgE levels may also be reported in",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and the conversion between these units is 1",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    = 2.44",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    half-life of free IgE in the serum is about two days, although once IgE has bound to mast cells, the half-life is extended to about two weeks due to the high affinity of this interaction [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745125\">",
"    <span class=\"h2\">",
"     Childhood levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE is not believed to cross the placenta. Therefore, a woman&rsquo;s allergen sensitivities are not passed on directly to her offspring through IgE transfer. However, allergens can be passed transplacentally, and the fetus can produce allergen-specific IgE. Routine allergen-specific IgE immunoassays cannot distinguish infant from maternal IgE, although a highly sensitive investigational microarray technique has demonstrated that infants can have IgE specific to food and inhalant allergens already present at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Levels increase from birth and peak between 16 to 19 years of age (",
"    <a class=\"graphic graphic_figure graphicRef83424 \" href=\"UTD.htm?32/11/32958\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/33\">",
"     33",
"    </a>",
"    ]. Preschool levels do not correlate well with those at older ages. Factors associated with increased levels of total IgE include male gender, African-American race, poverty, increased serum cotinine, less than a 12",
"    <sup>",
"     th",
"    </sup>",
"    grade education, and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In atopic individuals, total serum IgE levels may fluctuate. For example, in pollen-sensitized individuals, serum IgE levels peak four to six weeks after the height of pollen season and subsequently decline until next pollen season [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745133\">",
"    <span class=\"h3\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human breast milk has negligible amounts of IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, the serum IgE level of a breastfeeding mother appears to influence the serum level of her infant. Children of mothers with high IgE levels who breastfed their children for four months or longer had higher total IgE levels than bottlefed infants or infants breastfed for less than four months [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/36\">",
"     36",
"    </a>",
"    ]. In contrast, breastfed infants of mothers with low IgE levels were more likely to have lower IgE levels than the bottlefed or less than four months of breastfeeding infants. Paternal IgE levels did not have a detectable influence on children&rsquo;s IgE levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745141\">",
"    <span class=\"h2\">",
"     Decreased total IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most assays can only detect IgE levels as low as 2 to 5",
"    <span class=\"nowrap\">",
"     IU/mL,",
"    </span>",
"    with lower levels characterized as undetectable. Accordingly, IgE deficiency had been defined as levels &lt;2.5",
"    <span class=\"nowrap\">",
"     IU/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Mice",
"    with IgE deficiency are still capable of clearing parasites and having anaphylaxis, but the latter phenomenon appears to be due to an IgG-dependent pathway that may not exist in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/4\">",
"     4",
"    </a>",
"    ]. In humans, decreased IgE levels can be associated with decreased levels of other immunoglobulins and with sinopulmonary disease and an increased prevalence of autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. It is currently unclear if isolated IgE deficiency in humans is a clinically relevant immunodeficiency or a marker of more general immune dysregulation. The clinical manifestations of selective IgE deficiency are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/44/38597?source=see_link\">",
"     \"Selective IgE deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745149\">",
"    <span class=\"h2\">",
"     Increased total IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased serum IgE is seen in allergic diseases, some primary immunodeficiencies, parasitic and viral infections, certain inflammatory diseases, some malignancies, and a handful of other disorders (",
"    <a class=\"graphic graphic_table graphicRef83457 \" href=\"UTD.htm?29/49/30492\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745157\">",
"    <span class=\"h3\">",
"     Atopic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased serum IgE is associated with allergic and respiratory diseases such as atopic dermatitis, allergic bronchopulmonary aspergillosis (ABPA), asthma, persistent wheezing in children, and airway hyperresponsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30056?source=see_link&amp;anchor=H1127469#H1127469\">",
"     \"The relationship between IgE and allergic disease\", section on 'Elevated total serum IgE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745166\">",
"    <span class=\"h3\">",
"     Immunodeficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several primary immunodeficiencies are associated with elevated levels of IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/5,11,39,40\">",
"     5,11,39,40",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    It is unclear what pathologic role, if any, the increased IgE level has in these disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with Hyper-IgE syndrome (Job syndrome) have increased total IgE, usually ranging from 2000 to greater than 50,000",
"      <span class=\"nowrap\">",
"       IU/mL.",
"      </span>",
"      Hyper-IgE syndrome is characterized by eczema, retained primary teeth, joint hyperextensibility, characteristic facies, and pathologic fractures. These patients are more susceptible to fungal and",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      infections of the skin (skin abscesses) and lungs, including pneumatoceles. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=see_link\">",
"       \"Hyperimmunoglobulin E syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Netherton syndrome (cutaneous ichthyosis) is a rare autosomal recessive disorder due to a deficiency in SPINK5 (skin specific protease inhibitor Kazal type 5) leading to IgE sensitization via a damaged skin barrier. Total IgE levels may range from 100 to over 10,000",
"      <span class=\"nowrap\">",
"       IU/ml.",
"      </span>",
"      Presentation may be similar to Hyper-IgE syndrome, except ichthyosis and bamboo hair (trichorrhexis invaginata) occur in Netherton syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link&amp;anchor=H6#H6\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\", section on 'Spink 5'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunodysregulation polyendocrinopathy, enteropathy, X-linked (IPEX) is a rare X-linked primary immune deficiency with autoimmunity composed of a triad of enteropathy, endocrinopathy (diabetes or hypothyroid), and eczema. Patients have increased IgE and IgA with reduced or absent T regulatory cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=see_link\">",
"       \"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wiskott-Aldrich syndrome, a rare X-linked syndrome due to mutations in the Wiskott-Aldrich syndrome protein (WASP), is associated with eczema, thrombocytopenia, variable T cell function, and increased IgE levels. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Omenn syndrome presents with erythroderma, failure to thrive, diarrhea, hepatosplenomegaly, lymphadenopathy, eosinophilia, increased IgE, and decreased IgG, IgA, and IgM. Omenn syndrome is a combined B and T cell immunodeficiency due to hypomorphic mutations in",
"      <em>",
"       RAG1, RAG2",
"      </em>",
"      , or",
"      <em>",
"       ARTEMIS",
"      </em>",
"      altering T cell receptor rearrangement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link&amp;anchor=H13#H13\">",
"       \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\", section on 'Omenn syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One phenotype of complete DiGeorge syndrome has oligoclonal T-cell expansion with elevated IgE levels, in addition to the classic midline deficits (thymic hypoplasia, cardiac defects, parathyroid disease, cleft palate, and classic facies). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=see_link\">",
"       \"DiGeorge syndrome: Epidemiology and pathogenesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=see_link\">",
"       \"DiGeorge syndrome: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745174\">",
"    <span class=\"h3\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections with certain parasites and viruses are associated with an elevated serum IgE. In the developing world, parasitic infection is the most common cause of elevations in IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/5,11,39\">",
"     5,11,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A primary role for IgE is combating parasitic diseases. Parasites that are known to increase serum IgE include Strongyloides, Toxocara, Trichuris, Ascaris, Echinococcus, hookworms, filaria, and Schistosoma. Increased IgE levels reflect both parasite-specific IgE and total IgE [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. Increasing levels of IgE appear associated with increasing tissue invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/11\">",
"       11",
"      </a>",
"      ]. A peripheral blood eosinophilia is usually also present.",
"     </li>",
"     <li>",
"      Patients with human immunodeficiency virus type 1 (HIV) have elevated IgE levels, as well as increased allergic reactions to drugs or environmental allergens [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/11,43,44\">",
"       11,43,44",
"      </a>",
"      ]. In HIV-positive adults, elevated IgE levels may be partially related to various other conditions, such as intravenous drug use and alcohol intake [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Viral infections associated with elevated IgE levels include Epstein-Barr virus and cytomegalovirus. In EBV mononucleosis, IgE levels increase initially and return to baseline within weeks to months [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated IgE levels may be seen in infections with Mycobacterium tuberculosis [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/47-49\">",
"       47-49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745182\">",
"    <span class=\"h3\">",
"     Inflammatory diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Churg-Strauss syndrome features include elevated IgE (up to 5000",
"    <span class=\"nowrap\">",
"     IU/mL),",
"    </span>",
"    as well as necrotizing small and medium-sized vessel vasculitis and eosinophilia associated with asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=see_link\">",
"     \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kimura disease is a rare benign chronic inflammatory disorder with lymphadenopathy and eosinophilic adenitis of the head and neck regions of middle-aged Asian males. In addition to IgE levels greater than 1000",
"    <span class=\"nowrap\">",
"     IU/ml,",
"    </span>",
"    peripheral eosinophilia is present [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=see_link&amp;anchor=H5#H5\">",
"     \"Diseases with eosinophilic involvement of specific organs\", section on 'Kimura disease and angiolymphoid hyperplasia with eosinophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745190\">",
"    <span class=\"h3\">",
"     Neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplasms that have been reported in association with elevations in IgE include Hodgkin and non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/51-54\">",
"     51-54",
"    </a>",
"    ], especially nodular sclerotic histology, cutaneous T cell",
"    <span class=\"nowrap\">",
"     lymphoma/Sezary",
"    </span>",
"    syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], and IgE myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/39\">",
"     39",
"    </a>",
"    ]. IgE myelomas are extremely rare (0.01 percent of plasmacytomas) with serum IgE levels ranging from 0.6 to 63",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/11,57-61\">",
"     11,57-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745198\">",
"    <span class=\"h3\">",
"     Other disorders",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with bone marrow transplantation, IgE levels can increase up to 2000-fold, even in patients without graft-versus-host disease [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nephrotic syndrome associated with different forms of glomerulonephritis is associated with increased levels of IgE that decrease with therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/64-66\">",
"       64-66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cigarette smokers often have increased IgE levels compared to nonsmokers, especially in men [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/67,68\">",
"       67,68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alcohol consumption increases serum IgE levels [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31848/abstract/69,70\">",
"       69,70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745206\">",
"    <span class=\"h1\">",
"     ANTI-IgE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     Omalizumab",
"    </a>",
"    (Xolair) is a recombinant humanized monoclonal antibody that binds to the C&epsilon;3 portion of free serum IgE. It is approved for the treatment of perennial moderate to severe chronic persistent allergic asthma. It has been shown to be effective for other IgE-mediated diseases as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link\">",
"     \"Anti-IgE therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13745214\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgE is important in defense against some parasitic diseases and in mast cell and basophil degranulation and antigen presentation. IgE is central to the pathogenesis of many allergic diseases. (See",
"      <a class=\"local\" href=\"#H13745037\">",
"       'Roles of IgE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgE is produced by plasma cells. Isotype switching of B cells to produce antigen-specific IgE requires interleukins 4 and 13, and interactions between B and T cells. Antigen-specific IgE production primarily takes place in mucosal lymphoid tissues, particularly the tonsils and adenoids. (See",
"      <a class=\"local\" href=\"#H13745053\">",
"       'Synthesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgE functions through its high (Fc&epsilon;RI) and low (Fc&epsilon;RII) affinity receptors on mast cells, basophils and other cells leading to degranulation of mast cells, and basophils and antigen presentation.",
"      <sup>",
"      </sup>",
"      Expression of both receptors is positively correlated to circulating IgE levels. (See",
"      <a class=\"local\" href=\"#H13745061\">",
"       'IgE Receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Total IgE levels are frequently measured by a sandwich-type assay. Most assays can only detect IgE levels as low as 2 to 5",
"      <span class=\"nowrap\">",
"       IU/mL,",
"      </span>",
"      with lower levels characterized as undetectable. Normal serum levels range from approximately undetectable to 100",
"      <span class=\"nowrap\">",
"       IU/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H13745085\">",
"       'Measurement of IgE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgE is not transferred across the placenta. Levels increase from birth and peak between 16 to 19 years of age (",
"      <a class=\"graphic graphic_figure graphicRef83424 \" href=\"UTD.htm?32/11/32958\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13745109\">",
"       'IgE levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgE deficiency is defined as levels of total IgE &lt;2.5",
"      <span class=\"nowrap\">",
"       IU/mL.",
"      </span>",
"      Decreased IgE levels can be associated with deficiencies of other immunoglobulins and with sinopulmonary disease and autoimmune diseases, although it is unclear if isolated IgE deficiency in humans is a clinically relevant immunodeficiency or a marker of more general immune dysregulation. (See",
"      <a class=\"local\" href=\"#H13745141\">",
"       'Decreased total IgE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased total serum IgE is seen in allergic diseases, some primary immunodeficiencies, parasitic and viral infections, certain inflammatory diseases, some malignancies, and a handful of other disorders (",
"      <a class=\"graphic graphic_table graphicRef83457 \" href=\"UTD.htm?29/49/30492\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13745149\">",
"       'Increased total IgE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatments aimed at blocking IgE and decreasing IgE receptor expression are important therapeutic strategies in managing allergic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link\">",
"       \"Anti-IgE therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/1\">",
"      Oettgen HC, Geha RS. IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 2001; 107:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/2\">",
"      McSharry C, Xia Y, Holland CV, Kennedy MW. Natural immunity to Ascaris lumbricoides associated with immunoglobulin E antibody to ABA-1 allergen and inflammation indicators in children. Infect Immun 1999; 67:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/3\">",
"      Lynch NR, Hagel IA, Palenque ME, et al. Relationship between helminthic infection and IgE response in atopic and nonatopic children in a tropical environment. J Allergy Clin Immunol 1998; 101:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/4\">",
"      Watanabe N, Katakura K, Kobayashi A, et al. Protective immunity and eosinophilia in IgE-deficient SJA/9 mice infected with Nippostrongylus brasiliensis and Trichinella spiralis. Proc Natl Acad Sci U S A 1988; 85:4460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/5\">",
"      Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010; 125:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/6\">",
"      Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/7\">",
"      Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/8\">",
"      Vercelli D. Genetic regulation of IgE responses: Achilles and the tortoise. J Allergy Clin Immunol 2005; 116:60.",
"     </a>",
"    </li>",
"    <li>",
"     Vercelli D. Immunobiology of IgE. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby Elsevier, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/10\">",
"      Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol 2003; 3:721.",
"     </a>",
"    </li>",
"    <li>",
"     Smith P, Ownby DR. Clinical significance of IgE. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby Elsevier, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/12\">",
"      Eckl-Dorna J, Pree I, Reisinger J, et al. The majority of allergen-specific IgE in the blood of allergic patients does not originate from blood-derived B cells or plasma cells. Clin Exp Allergy 2012; 42:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/13\">",
"      Cameron L, Gounni AS, Frenkiel S, et al. S epsilon S mu and S epsilon S gamma switch circles in human nasal mucosa following ex vivo allergen challenge: evidence for direct as well as sequential class switch recombination. J Immunol 2003; 171:3816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/14\">",
"      Coker HA, Durham SR, Gould HJ. Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol 2003; 171:5602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/15\">",
"      Takhar P, Smurthwaite L, Coker HA, et al. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol 2005; 174:5024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/16\">",
"      Takhar P, Corrigan CJ, Smurthwaite L, et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol 2007; 119:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/17\">",
"      Balzar S, Strand M, Rhodes D, Wenzel SE. IgE expression pattern in lung: relation to systemic IgE and asthma phenotypes. J Allergy Clin Immunol 2007; 119:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/18\">",
"      Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/19\">",
"      Fregonese L, Patel A, van Schadewijk A, et al. Expression of the high-affinity IgE receptor (FcepsilonRI) is increased in fatal asthma. Am J Respir Crit Care 2004; 169:A297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/20\">",
"      Weidinger S, Gieger C, Rodriguez E, et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. PLoS Genet 2008; 4:e1000166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/21\">",
"      Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010; 363:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/22\">",
"      Granada M, Wilk JB, Tuzova M, et al. A genome-wide association study of plasma total IgE concentrations in the Framingham Heart Study. J Allergy Clin Immunol 2012; 129:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/23\">",
"      Dullaers M, De Bruyne R, Ramadani F, et al. The who, where, and when of IgE in allergic airway disease. J Allergy Clin Immunol 2012; 129:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/24\">",
"      Hibbert RG, Teriete P, Grundy GJ, et al. The structure of human CD23 and its interactions with IgE and CD21. J Exp Med 2005; 202:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/25\">",
"      Tsicopoulos A, Joseph M. The role of CD23 in allergic disease. Clin Exp Allergy 2000; 30:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/26\">",
"      Cooper AM, Hobson PS, Jutton MR, et al. Soluble CD23 controls IgE synthesis and homeostasis in human B cells. J Immunol 2012; 188:3199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/27\">",
"      Poole JA, Meng J, Reff M, et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 2005; 116:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/28\">",
"      Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 2008; 100:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/29\">",
"      Hamilton RG, Franklin Adkinson N Jr. In vitro assays for the diagnosis of IgE-mediated disorders. J Allergy Clin Immunol 2004; 114:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/30\">",
"      Hamilton RG, Williams PB, Specific IgE Testing Task Force of the American Academy of Allergy, Asthma &amp; Immunology, American College of Allergy, Asthma and Immunology. Human IgE antibody serology: a primer for the practicing North American allergist/immunologist. J Allergy Clin Immunol 2010; 126:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/31\">",
"      Hamilton RG. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). J Allergy Clin Immunol 2006; 117:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/32\">",
"      Kamemura N, Tada H, Shimojo N, et al. Intrauterine sensitization of allergen-specific IgE analyzed by a highly sensitive new allergen microarray. J Allergy Clin Immunol 2012; 130:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/33\">",
"      Gergen PJ, Arbes SJ Jr, Calatroni A, et al. Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2009; 124:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/34\">",
"      Underdown BJ, Knight A, Papsin FR. The relative paucity of IgE in human milk. J Immunol 1976; 116:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/35\">",
"      Duch&eacute;n K, Bj&ouml;rkst&eacute;n B. Total IgE levels in human colostrum. Pediatr Allergy Immunol 1996; 7:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/36\">",
"      Wright AL, Sherrill D, Holberg CJ, et al. Breast-feeding, maternal IgE, and total serum IgE in childhood. J Allergy Clin Immunol 1999; 104:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/37\">",
"      Schoettler JJ, Schleissner LA, Heiner DC. Familial IgE deficiency associated with sinopulmonary disease. Chest 1989; 96:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/38\">",
"      Smith JK, Krishnaswamy GH, Dykes R, et al. Clinical manifestations of IgE hypogammaglobulinemia. Ann Allergy Asthma Immunol 1997; 78:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/39\">",
"      Pien GC, Orange JS. Evaluation and clinical interpretation of hypergammaglobulinemia E: differentiating atopy from immunodeficiency. Ann Allergy Asthma Immunol 2008; 100:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/40\">",
"      Ozcan E, Notarangelo LD, Geha RS. Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol 2008; 122:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/41\">",
"      Duarte J, Deshpande P, Guiyedi V, et al. Total and functional parasite specific IgE responses in Plasmodium falciparum-infected patients exhibiting different clinical status. Malar J 2007; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/42\">",
"      Varatharajalu R, Parandaman V, Ndao M, et al. Strongyloides stercoralis excretory/secretory protein strongylastacin specifically recognized by IgE antibodies in infected human sera. Microbiol Immunol 2011; 55:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/43\">",
"      Zar HJ, Latief Z, Hughes J, Hussey G. Serum immunoglobulin E levels in human immunodeficiency virus-infected children with pneumonia. Pediatr Allergy Immunol 2002; 13:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/44\">",
"      Bowser CS, Kaye J, Joks RO, et al. IgE and atopy in perinatally HIV-infected children. Pediatr Allergy Immunol 2007; 18:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/45\">",
"      Miguez-Burbano MJ, Shor-Posner G, Fletcher MA, et al. Immunoglobulin E levels in relationship to HIV-1 disease, route of infection, and vitamin E status. Allergy 1995; 50:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/46\">",
"      Bahna SL, Heiner DC, Horwitz CA. Sequential changes of the five immunoglobulin classes and other responses in infectious mononucleosis. Int Arch Allergy Appl Immunol 1984; 74:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/47\">",
"      Ellertsen LK, Storla DG, Diep LM, et al. Allergic sensitisation in tuberculosis patients at the time of diagnosis and following chemotherapy. BMC Infect Dis 2009; 9:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/48\">",
"      Kutlu A, Bozkanat E, Cift&ccedil;i F, et al. Effect of active tuberculosis on skin prick allergy tests and serum IgE levels. J Investig Allergol Clin Immunol 2008; 18:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/49\">",
"      Ohrui T, Zayasu K, Sato E, et al. Pulmonary tuberculosis and serum IgE. Clin Exp Immunol 2000; 122:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/50\">",
"      Abuel-Haija M, Hurford MT. Kimura disease. Arch Pathol Lab Med 2007; 131:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/51\">",
"      Eckschlager T, Prsa R, Hlad&iacute;kov&aacute; M, et al. Lymphocyte subpopulations and immunoglobulin levels in Hodgkin's disease survivors. Neoplasma 2004; 51:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/52\">",
"      Koutsonikolis A, Day N, Chamizo W, et al. Asymptomatic lymphoma associated with elevation of immunoglobulin E. Ann Allergy Asthma Immunol 1997; 78:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/53\">",
"      Miyake S, Yoshizawa Y, Ohkouchi Y, et al. Non-Hodgkin's lymphoma with pulmonary infiltrates mimicking miliary tuberculosis. Intern Med 1997; 36:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/54\">",
"      Young MC, Harfi H, Sabbah R, et al. A human T cell lymphoma secreting an immunoglobulin E specific helper factor. J Clin Invest 1985; 75:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/55\">",
"      Scala E, Abeni D, Palazzo P, et al. Specific IgE toward allergenic molecules is a new prognostic marker in patients with S&eacute;zary syndrome. Int Arch Allergy Immunol 2012; 157:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/56\">",
"      Kural YB, Su O, Onsun N, Uras AR. Atopy, IgE and eosinophilic cationic protein concentration, specific IgE positivity, eosinophil count in cutaneous T Cell lymphoma. Int J Dermatol 2010; 49:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/57\">",
"      Talamo G, Castellani W, Dolloff NG. Prozone effect of serum IgE levels in a case of plasma cell leukemia. J Hematol Oncol 2010; 3:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/58\">",
"      Takemura Y, Ikeda M, Kobayashi K, et al. Plasma cell leukemia producing monoclonal immunoglobulin E. Int J Hematol 2009; 90:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/59\">",
"      Hua J, Hagihara M, Inoue M, Iwaki Y. A case of IgE-multiple myeloma presenting with a high serum Krebs von den Lungen-6 level. Leuk Res 2012; 36:e107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/60\">",
"      Lloyd L, Klingberg SL, Kende M, et al. A case of IgE multiple myeloma. Pathology 2003; 35:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/61\">",
"      Wang ML, Huang Q, Yang TX. IgE myeloma with elevated level of serum CA125. J Zhejiang Univ Sci B 2009; 10:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/62\">",
"      Ringd&eacute;n O, Persson U, Johansson SG, et al. Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. Blood 1983; 61:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/63\">",
"      Geha RS, Rappaport JM, Twarog FJ, et al. Increased serum immunoglobulin E levels following allogeneic bone marrow transplantation. J Allergy Clin Immunol 1980; 66:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/64\">",
"      Tan Y, Yang D, Fan J, Chen Y. Elevated levels of immunoglobulin E may indicate steroid resistance or relapse in adult primary nephrotic syndrome, especially in minimal change nephrotic syndrome. J Int Med Res 2011; 39:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/65\">",
"      Jahan I, Hanif M, Ali MA, et al. Relationship between serum IgE and frequent relapse idiopathic nephrotic syndrome. Mymensingh Med J 2011; 20:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/66\">",
"      Shao YN, Chen YC, Jenq CC, et al. Serum immunoglobulin E can predict minimal change disease before renal biopsy. Am J Med Sci 2009; 338:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/67\">",
"      Bonnin AJ, Montealegre F, Gewurz A. Association of cigarette smoking with elevated serum IgE levels in Hispanic Puerto Rican men. Ann Allergy 1991; 67:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/68\">",
"      Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010; 34:J258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/69\">",
"      Gonz&aacute;lez-Quintela A, Vidal C, Gude F. Alcohol-induced alterations in serum immunoglobulin e (IgE) levels in human subjects. Front Biosci 2002; 7:e234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31848/abstract/70\">",
"      Friedrich N, Husemoen LL, Petersmann A, et al. The association between alcohol consumption and biomarkers of alcohol exposure with total serum immunoglobulin E levels. Alcohol Clin Exp Res 2008; 32:983.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5542 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31848=[""].join("\n");
var outline_f31_6_31848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13745214\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13745029\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13745037\">",
"      ROLES OF IgE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13745045\">",
"      STRUCTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13745053\">",
"      SYNTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1397010\">",
"      Localized IgE production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264545938\">",
"      Regulation of synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13745061\">",
"      IgE RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13745069\">",
"      High affinity receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13745077\">",
"      Low affinity receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13745085\">",
"      MEASUREMENT OF IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13745093\">",
"      Total IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13745101\">",
"      Allergen-specific IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15831806\">",
"      Affect of omalizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13745109\">",
"      IgE LEVELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13745117\">",
"      Normal levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13745125\">",
"      Childhood levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13745133\">",
"      - Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13745141\">",
"      Decreased total IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13745149\">",
"      Increased total IgE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13745157\">",
"      - Atopic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13745166\">",
"      - Immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13745174\">",
"      - Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13745182\">",
"      - Inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13745190\">",
"      - Neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13745198\">",
"      - Other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13745206\">",
"      ANTI-IgE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13745214\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5542\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5542|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/41/3733\" title=\"figure 1\">",
"      IgE structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/30/42469\" title=\"figure 2\">",
"      Allergen sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/11/32958\" title=\"figure 3\">",
"      IgE levels with age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5542|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/49/30492\" title=\"table 1\">",
"      Diff dx elevated IgE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=related_link\">",
"      Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15608?source=related_link\">",
"      DiGeorge syndrome: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=related_link\">",
"      Diseases with eosinophilic involvement of specific organs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=related_link\">",
"      Function and clinical applications of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=related_link\">",
"      IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=related_link\">",
"      Mast cell derived mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/44/38597?source=related_link\">",
"      Selective IgE deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30056?source=related_link\">",
"      The relationship between IgE and allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_6_31849="Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis";
var content_f31_6_31849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/6/31849/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31849/contributors\">",
"     Lee-may Chen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31849/contributors\">",
"     Jonathan S Berek, MD, MMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/6/31849/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31849/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/6/31849/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31849/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/6/31849/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cancer is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of ovarian malignancies (95 percent) are derived from epithelial cells; the remainder arise from other ovarian cell types (germ cell tumors, sex cord-stromal tumors) (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High grade serous epithelial ovarian carcinoma (EOC), fallopian tubal, and peritoneal carcinomas are considered a single clinical entity due to their shared clinical behavior and treatment. There is also accumulating evidence of a common pathogenesis for these carcinomas. We will use the term EOC to refer this group of malignancies in the discussion that follows. Distinctions between these conditions, where present, will be addressed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=see_link\">",
"     \"Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of EOC are reviewed here. An overview of these neoplasms can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\"",
"    </a>",
"    .) Related topics are discussed in detail separately, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening of asymptomatic women (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"       \"Screening for ovarian cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pathogenesis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=see_link\">",
"       \"Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Histopathology (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"       \"Epithelial ovarian cancer: Pathology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epidemiology and risk factors (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=see_link\">",
"       \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Early symptoms (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"       \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Staging and surgical treatment (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"       \"Epithelial ovarian cancer: Initial surgical management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adjuvant therapy (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=see_link\">",
"       \"Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of epithelial ovarian carcinoma (EOC), fallopian tubal carcinoma, and peritoneal carcinoma may be either acute or subacute. Women who present in an acute fashion are typically those with advanced disease who present with a condition that requires urgent care and evaluation (eg, pleural effusion, bowel obstruction).",
"   </p>",
"   <p>",
"    EOC may present in a subacute fashion (eg, adnexal mass, pelvic or abdominal pain, gastrointestinal symptoms) in women with either early or advanced disease. These conditions are usually evaluated in an outpatient setting.",
"   </p>",
"   <p>",
"    Infrequently, EOC is discovered at the time of surgery performed for another indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9533939\">",
"    <span class=\"h2\">",
"     Acute presentation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9533974\">",
"    <span class=\"h3\">",
"     Pleural effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial presentation for some women with EOC is shortness of breath due to a malignant pleural effusion. If chest imaging reveals a malignant pleural effusion, thoracentesis is performed. A finding of malignant m&uuml;llerian cells suggests a diagnosis of EOC, and the patient should be further evaluated with imaging of the pelvis and abdomen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H954746\">",
"     'Paracentesis, thoracentesis, image-guided biopsy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H954659\">",
"     'Pelvic and abdominal imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9533987\">",
"    <span class=\"h3\">",
"     Bowel obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women with EOC present with bowel obstruction, and may come to medical attention due to severe nausea and vomiting. The finding of an abdominal mass on imaging then results in an evaluation for EOC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H954659\">",
"     'Pelvic and abdominal imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17557798\">",
"    <span class=\"h3\">",
"     Other acute presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, women with EOC present initially with venous thromboembolism (VTE). As an example, in a study that included over 12,000 patients with ovarian cancer, 27 were diagnosed with VTE during the year preceding their cancer diagnosis, representing a nearly threefold increase in the incidence of VTE compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/3\">",
"     3",
"    </a>",
"    ]. In another study that included 668 patients who had cancer at the time of an episode of VTE, 5.2 percent of the malignancies were ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of screening for malignancy in patients with venous thromboembolism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H7#H7\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Occult malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9533947\">",
"    <span class=\"h2\">",
"     Subacute presentation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13734856\">",
"    <span class=\"h3\">",
"     Adnexal mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of an adnexal mass on pelvic examination or imaging is a common presentation of ovarian cancer. An adnexal mass may be discovered due to symptoms of pelvic pain or pressure or it may be found on a routine pelvic examination or an imaging study performed for another indication. Women with advanced disease may present with a pelvic mass that extends beyond the adnexa.",
"   </p>",
"   <p>",
"    The clinical presentation of women with an adnexal mass is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099199\">",
"    <span class=\"h3\">",
"     Pelvic and abdominal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;EOC had historically been thought to be a silent disease. However, studies have found that symptoms occur in many women even at early stages [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. Symptoms that may be present in women with EOC include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bloating",
"     </li>",
"     <li>",
"      Urinary urgency or frequency",
"     </li>",
"     <li>",
"      Difficulty eating or feeling full quickly",
"     </li>",
"     <li>",
"      Pelvic or abdominal pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The type or severity of symptom does not reliably correspond to disease stage. The pathophysiology of abdominal symptoms in women with disease confined to the ovary or pelvis is not well understood. In women with advanced disease, abdominal distention, nausea, anorexia, or early satiety are typically due to the presence of ascites and omental or bowel metastases.",
"   </p>",
"   <p>",
"    The symptoms associated with ovarian cancer are nonspecific, and may also be caused by gastrointestinal, urologic, or other conditions. Symptoms that warrant further evaluation for ovarian cancer are those that are of new onset, coexist with other symptoms, occur almost daily, and are more severe than expected. The Gynecologic Cancer Foundation, American Cancer Society, and Society of Gynecologic Oncologists issued a consensus statement regarding early symptoms in 2007 (",
"    <a class=\"graphic graphic_table graphicRef76135 \" href=\"UTD.htm?28/28/29132\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are anecdotal reports that women with tubal carcinoma present with more intense pain than those with an ovarian carcinoma, possibly due to tubal distension [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of pelvic or abdominal symptoms in the detection of ovarian cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"     \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9534089\">",
"    <span class=\"h3\">",
"     Other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women with EOC present with postmenopausal bleeding, although women with postmenopausal bleeding should be assessed for uterine pathology before proceeding with an evaluation for ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link&amp;anchor=H3#H3\">",
"     \"Postmenopausal uterine bleeding\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rectal bleeding is present in some women with EOC, but it is unlikely to be the only presenting symptom and warrants further evaluation for EOC only if other clinical features of EOC are present (eg, adnexal mass, hereditary ovarian cancer syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7272?source=see_link\">",
"     \"Etiology of lower gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For fallopian tubal carcinoma, a classic triad of symptoms has been described: clear or blood-tinged vaginal discharge, pelvic pain, and a pelvic mass. The vaginal discharge, referred to as hydrops tubae profluens, has been regarded as pathognomonic for the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/15\">",
"     15",
"    </a>",
"    ]. However, vaginal discharge is not present in most women with fallopian tubal cancer (only 2 of 12 in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/16\">",
"     16",
"    </a>",
"    ]) and a complaint of vaginal discharge rarely results in the diagnosis of fallopian tubal carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099215\">",
"    <span class=\"h3\">",
"     Abdominal distention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal distention may be found on physical examination if a woman complains of bloating or abdominal enlargement, or it may be discovered incidentally during a routine abdominal examination. Abdominal distention associated with EOC is due to either ascites or bulky abdominal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of adults with ascites\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22680220\">",
"    <span class=\"h3\">",
"     Atypical glandular cells on cervical cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, women with EOC or fallopian tubal carcinoma present with atypical glandular cells on cervical cytology. A systematic review that included almost 7000 women with a Pap smear with atypical glandular cells found that 6.4 percent had ovarian or fallopian tubal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/17\">",
"     17",
"    </a>",
"    ]. Women with a finding of atypical glandular cells should be evaluated for cervical and endometrial carcinoma prior to pursuing further evaluation for other malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=see_link&amp;anchor=H481607#H481607\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\", section on 'Evaluation for ovarian cancer or other malignancies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8695634\">",
"    <span class=\"h3\">",
"     Paraneoplastic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, women with EOC may present with a paraneoplastic syndrome or may develop a syndrome during the course of the disease. Paraneoplastic syndromes associated with EOC include: cerebellar degeneration, polyneuritis, dermatomyositis, hemolytic anemia, disseminated intravascular coagulation, acanthosis, or nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/18\">",
"     18",
"    </a>",
"    ]. These syndromes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link\">",
"     \"Malignancy and rheumatic disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\", section on 'Association with malignancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link\">",
"     \"Hypercoagulable disorders associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link\">",
"     \"Cutaneous manifestations of internal malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4744?source=see_link\">",
"     \"Overview of renal disease associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17557852\">",
"    <span class=\"h3\">",
"     Other subacute presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpable inguinal or cervical lymphadenopathy is an uncommon presentation of EOC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\", section on 'Localized lymphadenopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H586132\">",
"    <span class=\"h2\">",
"     Incidental operative finding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, ovarian cancer is discovered incidentally at the time of surgery for another indication. If malignancy is recognized intraoperatively, intraoperative consultation from a gynecologic oncologist should be requested, if available. If a gynecologic oncologist is not available and a surgeon is not experienced in operative management of ovarian cancer (eg, lymphadenectomy), it is prudent to terminate the surgery and arrange for prompt consultation with a specialist for a second procedure. (See",
"    <a class=\"local\" href=\"#H13734725\">",
"     'Referral to a specialist'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If ovarian cancer is discovered only upon histologic evaluation following surgery, the patient should be referred to a gynecologic oncologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13733315\">",
"    <span class=\"h1\">",
"     APPROACH TO EVALUATION OF WOMEN WITH SUSPECTED OVARIAN CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of epithelial ovarian (EOC), fallopian tubal, or peritoneal carcinoma requires surgical exploration. The primary reason for this is that women with early stage disease (ie, no malignant cells in ascites or peritoneal cytology) benefit from removal of the adnexal mass intact, since incising or rupturing the mass results in a more advanced stage of disease and adversely affects prognosis (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60565 \" href=\"UTD.htm?14/11/14526\">",
"     table 3",
"    </a>",
"    ). Thus, image-guided ovarian biopsy is generally not performed and unfortunately, many women undergo surgical procedures to identify the few who have a malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link&amp;anchor=H25#H25\">",
"     \"Oophorectomy and ovarian cystectomy\", section on 'Spillage of malignant cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are some exceptions to diagnosis via a surgical procedure. These include women who are poor candidates for aggressive initial surgical cytoreduction due to imaging findings of extensive disease (liver or pulmonary metastases, disease in the porta hepatis, or massive ascites) or with a poor performance status and who are best treated with neoadjuvant chemotherapy. These women are typically evaluated with imaging and either paracentesis, thoracentesis, or image-guided biopsy prior to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250841373#H250841373\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13733571\">",
"     'Assessing for metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The most important element of the evaluation is the finding of an adnexal mass on imaging. The usual indication for a surgical evaluation for ovarian or fallopian tubal carcinoma the finding of an adnexal mass that is suspicious for malignancy. In general, other features (eg, symptoms, risk factors, laboratory results) may contribute to the clinical suspicion of malignancy, but are usually not a sufficient indication for surgery. One exception to this is that some experts perform diagnostic laparoscopy for women who have both EOC-associated symptoms and an elevated tumor marker.",
"   </p>",
"   <p>",
"    Women with peritoneal carcinoma may present either with or without an adnexal mass. For these women, the decision to proceed with surgery is based upon either the combination of EOC-associated symptoms and an elevated tumor marker or upon imaging findings consistent with peritoneal carcinomatosis. (See",
"    <a class=\"local\" href=\"#H6099199\">",
"     'Pelvic and abdominal symptoms'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link&amp;anchor=H543206#H543206\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Laboratory studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of women with features suggestive of EOC is typically a two-phase process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial evaluation of women to determine whether an adnexal mass or elevated tumor markers are present and whether there is sufficient clinical suspicion of malignancy to proceed with surgery (see",
"      <a class=\"local\" href=\"#H6099223\">",
"       'Initial evaluation'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If there is no indication for diagnostic surgery (adnexal mass, EOC-associated symptoms and an elevated tumor marker, or peritoneal carcinomatosis), the clinician should pursue an evaluation for other etiologies of the patient&rsquo;s symptoms or signs.",
"     </li>",
"     <li>",
"      If an adnexal mass is found and based upon the initial evaluation, there is a suspicion of EOC, surgical evaluation is performed. Management of benign-appearing adnexal masses is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link\">",
"       \"Management of an adnexal mass\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical evaluation is preceded by a preoperative evaluation (see",
"      <a class=\"local\" href=\"#H13735423\">",
"       'Surgical evaluation'",
"      </a>",
"      below). The goals of the preoperative evaluation are to exclude metastatic disease, a synchronous primary cancer, and the possibility that the adnexal mass is due to metastases from an extraovarian (or extratubal) primary cancer. This evaluation may also result in the decision to treat with neoadjuvant chemotherapy prior to surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250841373#H250841373\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Neoadjuvant chemotherapy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Following the preoperative evaluation, surgical exploration is performed with removal of a specimen and histologic evaluation. (See",
"      <a class=\"local\" href=\"#H6099260\">",
"       'Diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099223\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the initial evaluation for epithelial ovarian carcinoma (EOC), fallopian tubal, or peritoneal carcinoma is to determine the degree of clinical suspicion of malignancy. If there is a high likelihood of malignancy, the patient should be referred to a gynecologic oncologist (",
"    <a class=\"graphic graphic_table graphicRef55063 \" href=\"UTD.htm?7/38/7787\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13734725\">",
"     'Referral to a specialist'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Women with symptoms and findings suggestive of EOC should be evaluated for an adnexal mass with pelvic examination and pelvic imaging. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Clinical presentation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link&amp;anchor=H25408488#H25408488\">",
"     \"Approach to the patient with an adnexal mass\", section on 'General evaluation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Once an adnexal mass has been identified, the evaluation to exclude malignancy includes a medical history, physical examination, imaging studies, and laboratory evaluation for tumor markers. The evaluation of an adnexal mass is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link&amp;anchor=H3884375#H3884375\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Evaluation for malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The process of evaluation differs somewhat for women with peritoneal carcinoma, since they may present without an adnexal mass. For these women, a symptom of abdominal bloating",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a finding of abdominal distension on examination should be evaluated with a pelvic and abdominal imaging study. Peritoneal carcinoma is then suspected if the imaging study is consistent with peritoneal carcinomatosis. (See",
"    <a class=\"local\" href=\"#H13733571\">",
"     'Assessing for metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13735423\">",
"    <span class=\"h1\">",
"     SURGICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical exploration is performed if there is sufficient suspicion of epithelial ovarian carcinoma (EOC), fallopian tubal, or peritoneal carcinoma, based upon the initial evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13733533\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative evaluation helps to guide surgical planning and includes the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess the ability to tolerate surgery &ndash; Patients who are elderly or have medical comorbidities require medical clearance prior to surgery. In the rare case in which the patient is not a candidate for surgery, an image-guided biopsy of the ovary (or alternatively, paracentesis or image-guided biopsy of intraabdominal disease) is performed to confirm the presence of EOC prior to treatment with chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41735?source=see_link\">",
"       \"Overview of the principles of medical consultation and perioperative medicine\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H954746\">",
"       'Paracentesis, thoracentesis, image-guided biopsy'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"     <li>",
"      Assess for metastatic disease",
"     </li>",
"     <li>",
"      Exclude metastatic disease from another primary cancer",
"     </li>",
"     <li>",
"      Exclude a synchronous malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13733571\">",
"    <span class=\"h3\">",
"     Assessing for metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history and physical examination of all women with suspected EOC should include an assessment for symptoms and findings associated with metastatic disease (eg, gastrointestinal symptoms, abdominal distention, ascites, pleural effusion, inguinal or cervical lymphadenopathy). Women with these clinical features should undergo further evaluation with pelvic and abdominal imaging.",
"   </p>",
"   <p>",
"    Preoperative assessment for metastatic disease helps to identify patients who should be referred to a gynecologic oncologist (see",
"    <a class=\"local\" href=\"#H13734725\">",
"     'Referral to a specialist'",
"    </a>",
"    below). It also helps the surgeon to anticipate the need for cytoreduction and to identify women who are poor candidates for aggressive initial surgical cytoreduction due to imaging findings of extensive disease (liver or pulmonary metastases, disease in the porta hepatis, or massive ascites) and may be candidates for neoadjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250841373#H250841373\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, women with peritoneal carcinomatosis in the absence of an adnexal mass may have peritoneal carcinoma. Surgical exploration is required for patients with peritoneal carcinomatosis, regardless of the etiology. However, prior to surgery, women should also be assessed for risk factors or elevated tumor markers that contribute to the preoperative suspicion of peritoneal carcinoma rather than other intraabdominal malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link&amp;anchor=H10#H10\">",
"     \"Adenocarcinoma of unknown primary site\", section on 'Women with peritoneal carcinomatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H954659\">",
"    <span class=\"h4\">",
"     Pelvic and abdominal imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies can help to assess for the presence of ascites and the extent of disease in women with suspected intraabdominal spread of EOC. Abdominal and pelvic computerized tomography (CT) or magnetic resonance imaging (MRI) are the most commonly used modalities. In our practice, we obtain an abdominal and pelvic CT because it is less expensive and more comfortable for the patient than MRI. If the patient has a contrast allergy that precludes use of CT, we order an MRI.",
"   </p>",
"   <p>",
"    Some data suggest that positron emission tomography alone or combined with CT increases the detection of metastatic EOC compared with CT alone or MRI; further study of the preoperative use of this imaging modality is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H827195\">",
"    <span class=\"h4\">",
"     Other imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiography is performed in most patients to evaluate for pleural effusion, pulmonary metastases, and mediastinal lymphadenopathy. In some institutions, chest CT is performed at the time of abdominal and pelvic CT.",
"   </p>",
"   <p>",
"    Liver-spleen scans, bone scans, and brain scans are unnecessary unless symptoms or signs suggest metastases to these sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H954746\">",
"    <span class=\"h4\">",
"     Paracentesis, thoracentesis, image-guided biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, if there is diagnostic uncertainty or if neoadjuvant chemotherapy is being considered rather than initial surgery, other studies may be used to determine the diagnosis, including (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250841373#H250841373\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with ascites, paracentesis may be performed.",
"     </li>",
"     <li>",
"      In patients with pleural effusion, thoracentesis may be performed. In addition, some data suggest that evaluation with biopsy performed using video-assisted thoracic surgery may help guide treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with peritoneal carcinomatosis or an omental cake, image-guided biopsy is an option. This approach was illustrated in a retrospective case series, in which CT- or ultrasound-guided biopsy provided a site-specific diagnosis in 93 percent of women with peritoneal carcinomatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of image-guide biopsy of the ovary is limited to the rare cases in which a woman is not a surgical candidate and there is no evidence of intraabdominal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13733674\">",
"    <span class=\"h3\">",
"     Excluding an extraovarian primary cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal cancers and breast cancer are the most common nongenital malignancies that metastasize to the ovary. In studies of 50 or more cases of metastatic neoplasms to the ovary, the sites of primary tumors included: colon cancer (15 to 32 percent); breast (8 to 28 percent); gastric (6 to 22 percent); and appendix (2 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial evaluation of women with suspected EOC should include questions about gastrointestinal symptoms and abdominal and breast examination. Women should undergo appropriate screening for breast and cervical cancer prior to surgical exploration. Further evaluation should be performed if one of these malignancies is suspected. &nbsp;",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of gastrointestinal and breast cancers are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among gynecologic malignancies, endometrial cancer is the most likely to present with an adnexal mass. If abnormal uterine bleeding or a uterine mass is present, endometrial sampling should be performed preoperatively. Cervical, vaginal, or vulvar cancer are not commonly mistaken for ovarian cancer. These tumors may present with a pelvic mass, but it is not likely be an isolated adnexal mass. In addition, there is also typically a mass at the site of origin of these cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link\">",
"     \"Vaginal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13733905\">",
"    <span class=\"h3\">",
"     Excluding a synchronous primary cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synchronous primary cancers of the ovary and endometrium have been reported in about 10 percent of women with ovarian cancer and 5 percent of women with endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/26\">",
"     26",
"    </a>",
"    ]. Women at an increased risk for both ovarian and endometrial cancer are those with Lynch syndrome (",
"    <a class=\"graphic graphic_figure graphicRef57830 \" href=\"UTD.htm?2/0/2049\">",
"     figure 2",
"    </a>",
"    ) and those with an estrogen-secreting tumor (although these are sex cord-stromal tumors rather than epithelial carcinoma (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 5",
"    </a>",
"    )). Other risk factors for synchronous cancers include younger age, obesity, premenopausal status, and nulliparity, which suggest a hormonal effect [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=see_link&amp;anchor=H9#H9\">",
"     \"Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Synchronous and metachronous cancers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H843444#H843444\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Estrogen-secreting tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If abnormal uterine bleeding or a uterine mass is present, endometrial sampling should be performed preoperatively. Treatment is based upon the combined treatment recommendations for each cancer according to stage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13733541\">",
"    <span class=\"h2\">",
"     Surgical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of surgery is to confirm whether malignancy is present, and if so, proceed with staging and cytoreduction. The steps of this procedure are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6099260\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial ovarian cancer (EOC), fallopian tubal carcinoma, and peritoneal carcinoma are histologic diagnoses. This evaluation is performed following surgical removal of an ovary or fallopian tube or biopsies of the peritoneum. Infrequently (approximately 20 percent of women with advanced disease will be managed this way), the diagnosis is based upon tissue or fluid obtained via image-guided biopsy, paracentesis, or thoracentesis. (See",
"    <a class=\"local\" href=\"#H954746\">",
"     'Paracentesis, thoracentesis, image-guided biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    High grade serous EOC, fallopian tubal, and peritoneal carcinomas are considered a single clinical entity due to their shared clinical behavior and treatment, and there is accumulating evidence of a common pathogenesis. Traditionally, clinicians attempted to distinguish between these malignancies and assigned an apparent primary site (ie, ovary, tube, or peritoneum) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, since treatment is the same for all three sites, in current practice, the clinical usefulness of assigning a primary site is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of epithelial ovarian carcinoma (EOC), tubal, or peritoneal carcinoma varies with the clinical presentation.",
"   </p>",
"   <p>",
"    Many of the symptoms associated with ovarian cancer (eg, abdominal pressure or pain, gastrointestinal symptoms, urologic symptoms) are nonspecific. In the absence of an adnexal mass, an evaluation should be performed for other conditions.",
"   </p>",
"   <p>",
"    Similarly, women who present with abdominal distention or ascites in the absence of an adnexal mass should undergo evaluation for other conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, even in the absence of an adnexal mass, if symptoms associated with EOC",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal distention or ascites are present and tumor markers associated with EOC are elevated, a diagnostic laparoscopy should be considered as part of the evaluation. (See",
"    <a class=\"local\" href=\"#H13733315\">",
"     'Approach to evaluation of women with suspected ovarian cancer'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There should be a high index of suspicion for peritoneal carcinoma if peritoneal carcinomatosis is found on imaging. However, findings suggestive of peritoneal carcinomatosis may result from other intraabdominal malignancies or metastasizing conditions associated with leiomyomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link\">",
"     \"Adenocarcinoma of unknown primary site\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=see_link&amp;anchor=H1167264#H1167264\">",
"     \"Variants of uterine leiomyomas (fibroids)\", section on 'Benign uterine variants with extrauterine disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postmenopausal bleeding is present in some women with EOC, but this is not a typical clinical presentation. Women with postmenopausal bleeding should be assessed for uterine pathology before proceeding with an evaluation for ovarian cancer. For women with both abnormal uterine bleeding and an adnexal mass, an evaluation of both the endometrium and of the adnexal mass should be pursued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an adnexal mass is present, it is more likely to be benign than malignant. The first step in the evaluation of an adnexal mass is to confirm the presence and anatomic location of the mass with pelvic imaging, usually ultrasound. The differential diagnosis of an adnexal mass is shown in the table and discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef69013 \" href=\"UTD.htm?20/40/21131\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link&amp;anchor=H3883656#H3883656\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Clinical approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13735199\">",
"    <span class=\"h1\">",
"     TESTING FOR HEREDITARY CANCER SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with suspected or confirmed epithelial ovarian cancer, a detailed family history of other malignancies should be elicited. This helps to identify women who should be evaluated for familial cancer syndromes (eg,",
"    <em>",
"     BRCA1",
"    </em>",
"    or",
"    <em>",
"     BRCA2",
"    </em>",
"    mutations, Lynch syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/30\">",
"     30",
"    </a>",
"    ]. Approximately 13 percent of women with invasive ovarian cancer have a",
"    <em>",
"     BRCA1",
"    </em>",
"    or",
"    <em>",
"     BRCA2",
"    </em>",
"    mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31849/abstract/31\">",
"     31",
"    </a>",
"    ]. The presence of a familial syndrome may impact treatment or posttreatment care. As an example, women with Lynch syndrome are at an increased risk of have a synchronous primary cancer at time of surgical staging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13734725\">",
"    <span class=\"h1\">",
"     REFERRAL TO A SPECIALIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a complex adnexal mass, findings suggestive of metastatic epithelial ovarian (EOC), fallopian tubal, or peritoneal carcinoma, or laboratory testing suggestive of ovarian cancer (eg, elevated serum CA 125) should be referred a gynecologist or gynecologic oncologist for further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link&amp;anchor=H3884375#H3884375\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Evaluation for malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women in whom there is a high suspicion of EOC should be referred to a gynecologic oncologist. There is evidence that prognosis is improved when EOC staging and cytoreduction is performed by a gynecologic oncologist. Criteria for referral to a gynecologic oncologist are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef55063 \" href=\"UTD.htm?7/38/7787\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=see_link\">",
"     \"Management of an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=see_link\">",
"       \"Patient information: Ovarian cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"       \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"       \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epithelial ovarian carcinoma (EOC), fallopian tubal carcinoma, and peritoneal carcinoma present most commonly with a pelvic mass",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pelvic or abdominal symptoms (",
"      <a class=\"graphic graphic_table graphicRef76135 \" href=\"UTD.htm?28/28/29132\">",
"       table 1",
"      </a>",
"      ). Acute presentations include malignant pleural effusion or bowel obstruction. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of women with features suggestive of EOC is typically a two-phase process: an initial evaluation to determine whether an adnexal mass is present followed by surgical evaluation, staging, and cytoreduction. (See",
"      <a class=\"local\" href=\"#H13733315\">",
"       'Approach to evaluation of women with suspected ovarian cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical evaluation is typically required because women with early stage disease benefit from removal of the adnexal mass intact, since incising or rupturing the mass results in a more advanced stage of disease and adversely affects prognosis. (See",
"      <a class=\"local\" href=\"#H13733315\">",
"       'Approach to evaluation of women with suspected ovarian cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preoperative evaluation helps to guide surgical planning by assessing for metastatic disease, an extraovarian primary cancer metastatic to the ovary, and a synchronous primary cancer. (See",
"      <a class=\"local\" href=\"#H13733533\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EOC, fallopian tubal carcinoma, and peritoneal carcinoma are histologic diagnoses. This evaluation is performed following surgical removal of an ovary or fallopian tube or biopsies of the peritoneum. (See",
"      <a class=\"local\" href=\"#H6099260\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of an adnexal mass includes both benign and malignant conditions that are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef69013 \" href=\"UTD.htm?20/40/21131\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with suspected or confirmed EOC, a detailed family history of other malignancies to identify women who should be evaluated for familial cancer syndromes (eg,",
"      <em>",
"       BRCA1",
"      </em>",
"      or",
"      <em>",
"       BRCA2",
"      </em>",
"      mutations, Lynch syndrome). (See",
"      <a class=\"local\" href=\"#H13735199\">",
"       'Testing for hereditary cancer syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women in whom there is a high suspicion of EOC should be referred to a gynecologic oncologist (",
"      <a class=\"graphic graphic_table graphicRef55063 \" href=\"UTD.htm?7/38/7787\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13734725\">",
"       'Referral to a specialist'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.",
"     </a>",
"    </li>",
"    <li>",
"     Lacey JV, Sherman ME. Ovarian neoplasia. In: Robboy's Pathology of the Female Reproductive Tract, 2nd ed., Robboy SL, Mutter GL, Prat J, et al..  (Eds), Churchill Livingstone Elsevier, Oxford 2009. p.601.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/3\">",
"      White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/4\">",
"      S&oslash;rensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/5\">",
"      Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000; 89:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/6\">",
"      Olson SH, Mignone L, Nakraseive C, et al. Symptoms of ovarian cancer. Obstet Gynecol 2001; 98:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/7\">",
"      Vine MF, Ness RB, Calingaert B, et al. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol 2001; 83:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/8\">",
"      Yawn BP, Barrette BA, Wollan PC. Ovarian cancer: the neglected diagnosis. Mayo Clin Proc 2004; 79:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/9\">",
"      Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/10\">",
"      Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109:221.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.wcn.org/articles/types_of_cancer/ovarian/symptoms/index.html (Accessed on May 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/12\">",
"      Friedrich M, Villena-Heinsen C, Schweizer J, et al. Primary tubal carcinoma: a retrospective analysis of four cases with a literature review. Eur J Gynaecol Oncol 1998; 19:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/13\">",
"      Hippisley-Cox J, Coupland C. Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. BMJ 2012; 344:d8009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/14\">",
"      Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009; 339:b2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/15\">",
"      SINHA AC. Hydrops tubae profluens as a presenting symptom in primary carcinoma of the fallopian tube: report of two cases and review of literature. Br Med J 1959; 2:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/16\">",
"      Ou YC, Huang HY, Huang CC, et al. Primary fallopian tube carcinoma: clinicopathological analysis of 12 cases. Taiwan J Obstet Gynecol 2011; 50:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/17\">",
"      Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006; 107:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/18\">",
"      Shanbhogue AK, Shanbhogue DK, Prasad SR, et al. Clinical syndromes associated with ovarian neoplasms: a comprehensive review. Radiographics 2010; 30:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/19\">",
"      Musto A, Rampin L, Nanni C, et al. Present and future of PET and PET/CT in gynaecologic malignancies. Eur J Radiol 2011; 78:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/20\">",
"      Diaz JP, Abu-Rustum NR, Sonoda Y, et al. Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol Oncol 2010; 116:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/21\">",
"      Hewitt MJ, Anderson K, Hall GD, et al. Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis. BJOG 2007; 114:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/22\">",
"      Mehdi G, Maheshwari V, Afzal S, et al. Image-guided fine-needle aspiration cytology of ovarian tumors: An assessment of diagnostic efficacy. J Cytol 2010; 27:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/23\">",
"      Moore RG, Chung M, Granai CO, et al. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol 2004; 93:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/24\">",
"      de Waal YR, Thomas CM, Oei AL, et al. Secondary ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer 2009; 19:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/25\">",
"      Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C, et al. Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases. Arch Gynecol Obstet 2011; 284:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/26\">",
"      Zaino R, Whitney C, Brady MF, et al. Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol 2001; 83:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/27\">",
"      Soliman PT, Slomovitz BM, Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 2004; 94:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/28\">",
"      HU CY, TAYMOR ML, HERTIG AT. Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1950; 59:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/29\">",
"      Seidman JD, Zhao P, Yemelyanova A. \"Primary peritoneal\" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011; 120:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/30\">",
"      Meyer LA, Anderson ME, Lacour RA, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol 2010; 115:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31849/abstract/31\">",
"      Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; 121:353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3238 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31849=[""].join("\n");
var outline_f31_6_31849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9533939\">",
"      Acute presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9533974\">",
"      - Pleural effusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9533987\">",
"      - Bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17557798\">",
"      - Other acute presentations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9533947\">",
"      Subacute presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13734856\">",
"      - Adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6099199\">",
"      - Pelvic and abdominal symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9534089\">",
"      - Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6099215\">",
"      - Abdominal distention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22680220\">",
"      - Atypical glandular cells on cervical cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8695634\">",
"      - Paraneoplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17557852\">",
"      - Other subacute presentations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H586132\">",
"      Incidental operative finding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13733315\">",
"      APPROACH TO EVALUATION OF WOMEN WITH SUSPECTED OVARIAN CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099223\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13735423\">",
"      SURGICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13733533\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13733571\">",
"      - Assessing for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H954659\">",
"      Pelvic and abdominal imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H827195\">",
"      Other imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H954746\">",
"      Paracentesis, thoracentesis, image-guided biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13733674\">",
"      - Excluding an extraovarian primary cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13733905\">",
"      - Excluding a synchronous primary cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13733541\">",
"      Surgical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6099260\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13735199\">",
"      TESTING FOR HEREDITARY CANCER SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13734725\">",
"      REFERRAL TO A SPECIALIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3238|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44307\" title=\"figure 1\">",
"      Origins ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/0/2049\" title=\"figure 2\">",
"      Lynch syndrome cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3238|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/28/29132\" title=\"table 1\">",
"      Consensus statement ov ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 2\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/11/14526\" title=\"table 3\">",
"      Staging fallopian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/38/7787\" title=\"table 4\">",
"      Referral to gyn oncologist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/4/24653\" title=\"table 5\">",
"      Ovarian tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/40/21131\" title=\"table 6\">",
"      Differential dx adnexal mass",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=related_link\">",
"      Adenocarcinoma of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26231?source=related_link\">",
"      Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=related_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=related_link\">",
"      Early detection of epithelial ovarian cancer: Role of symptom recognition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18233?source=related_link\">",
"      Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25978?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7272?source=related_link\">",
"      Etiology of lower gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30905?source=related_link\">",
"      Management of an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4744?source=related_link\">",
"      Overview of renal disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41735?source=related_link\">",
"      Overview of the principles of medical consultation and perioperative medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28073?source=related_link\">",
"      Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=related_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=related_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/3/17465?source=related_link\">",
"      Variants of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_6_31850="Overview of the treatment of acute lymphoblastic leukemia in children";
var content_f31_6_31850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of acute lymphoblastic leukemia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/6/31850/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31850/contributors\">",
"     Terzah M Horton, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31850/contributors\">",
"     C Philip Steuber, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/6/31850/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31850/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?31/6/31850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?31/6/31850/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?31/6/31850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute leukemia is the most common form of cancer in children, comprising approximately 30 percent of all childhood malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/1\">",
"     1",
"    </a>",
"    ]. Of the acute leukemias, acute lymphoblastic leukemia (ALL) occurs five times more commonly than acute myeloid leukemia (AML). Survival rates for ALL have improved dramatically during the since the 1980s, with a current five-year overall survival rates estimated at greater than 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This improvement in survival is due to treatment of a large number of children on sequential standardized research protocols. Approximately 75 to 80 percent of children with newly diagnosed ALL participate in such trials, the goals of which are to improve clinical outcomes while minimizing acute toxicities and late-occurring adverse events.",
"   </p>",
"   <p>",
"    The treatment of ALL in children is reviewed here. The epidemiology, presentation, classification, risk group stratification, and outcome of childhood ALL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37753?source=see_link\">",
"     \"Risk group stratification and prognosis for acute lymphoblastic leukemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=see_link\">",
"     \"Overview of the outcome of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the majority of children with ALL will be cured, consultation with palliative care specialists may be considered at the time of diagnosis as with any life threatening condition. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28058?source=see_link\">",
"     \"Pediatric palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment of children with ALL involves administration of a multidrug regimen that is divided into several phases (ie, induction, consolidation, and maintenance) and includes therapy directed to the central nervous system (CNS). Most treatment protocols take two to three years to complete, although the specific regimen varies depending upon immunophenotype and risk category (",
"    <a class=\"graphic graphic_table graphicRef71649 \" href=\"UTD.htm?0/35/574\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37753?source=see_link\">",
"     \"Risk group stratification and prognosis for acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the time of diagnosis, patients with ALL commonly require transfusion support, treatment of suspected or proven infections with broad-spectrum antibiotics, and, for patients with a high tumor burden, correction of any metabolic imbalances such as hyperuricemia. A rare patient may require leukapheresis or exchange transfusion to control extreme leukocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=see_link\">",
"     \"Indications for red blood cell transfusion in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link&amp;anchor=H2#H2\">",
"     \"Uric acid renal diseases\", section on 'Acute uric acid nephropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite improvements in supportive care, death resulting from treatment toxicity remains a problem. In a review of over 1000 children with ALL treated at St. Jude Children's Research Hospital, the estimated 10-year cumulative incidence of treatment-related death was 2.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/5\">",
"     5",
"    </a>",
"    ]. Age was the only predictor of death; children in the age bracket from one to nine years had a significantly lower risk of treatment-related mortality than did either infants or older children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy is the initial phase of treatment and is designed to place the patient in remission. More than 90 percent of children and adolescents with ALL enter CR at the end of induction therapy regardless of their initial risk grouping [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/6-13\">",
"     6-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Induction therapy usually involves weekly administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    for three to four weeks, daily corticosteroids (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ), and asparaginase, either in its pegylated form (Oncaspar&reg;) or as 6 to 12 doses of L-asparaginase [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/14\">",
"     14",
"    </a>",
"    ]. A fourth agent such as an anthracycline (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/19/31029?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ) may be added to the three-dose regimen, particularly for high-risk patients. In addition, a tyrosine kinase inhibitor, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35352?source=see_link\">",
"     imatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , should be incorporated into the treatment of the rare patient with t(9;22) (Philadelphia chromosome) positive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Response to therapy is often assessed by bone marrow examination during the induction phase of treatment. The number and frequency of additional bone marrow examinations performed during induction has not been standardized. Because of this, the definition of \"rapid response\" and \"slow response\" vary between institutions. It is not uncommon, however, to employ a more aggressive treatment regimen if there is minimal or no response to initial induction therapy.",
"   </p>",
"   <p>",
"    Early clearance of lymphoblasts from the bone marrow and the presence of minimal residual disease (MRD) at day 15 and the end of induction therapy are the best indicators of outcome. Patients who respond rapidly to the induction regimen appear to have a more favorable outcome, whereas those who have a slow response or who fail induction therapy have a more guarded prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/7,19-23\">",
"     7,19-23",
"    </a>",
"    ]. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\", section on 'MRD in children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Induction failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction failure, which occurs in fewer than 5 percent of cases, is defined by the persistence of leukemic blasts in the blood, bone marrow, or any extramedullary site after four to six weeks of remission-induction therapy. Induction failure has historically been considered a particularly ominous sign and an indication for allogeneic hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/24\">",
"     24",
"    </a>",
"    ]. Due to the rarity of induction failure, information regarding this population has been limited to small numbers of patients enrolled on prospective trials [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An international retrospective analysis from 14 cooperative study groups identified 44,017 children (&le;18 years) with previously untreated ALL diagnosed from 1985 to 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/28\">",
"     28",
"    </a>",
"    ], of which 1041 (2.4 percent) had induction failure. In this cohort, patients with induction failure were more likely to have had at least one of the following unfavorable features at presentation: male sex, older age (&gt;6 years), high leukocyte count",
"    <span class=\"nowrap\">",
"     (&gt;100/microL),",
"    </span>",
"    T cell leukemia, CNS involvement, 11q23 (MLL) chromosomal rearrangement, or the t(9;22)(BCR-ABL1) translocation. These same unfavorable features, except for male sex and CNS involvement, were also associated with reduced survival after induction failure. At a median follow-up of 8.3 years, the estimated overall survival (OS) at 10 years for patients with induction failure who did not demonstrate t(9;22)(BCR-ABL1) was 32 percent. For the 624 patients with genetic data available, patients could be stratified by karyotype with the following estimated 10-year OS:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High hyperdiploid cytogenetics (N=55) &mdash; 72 percent",
"     </li>",
"     <li>",
"      Normal karyotype (N=159) &mdash; 36 percent",
"     </li>",
"     <li>",
"      Other chromosomal aberration (N=250) &mdash; 30 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       11q23/MLL",
"      </span>",
"      abnormality (N=50) &mdash; 16 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       t(9;22)/BCR-ABL1",
"      </span>",
"      (N=110) &mdash; 11 percent &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data highlight the heterogeneity of the induction-failure population and the need for individualized treatment decisions. Although the estimated OS rate was similar among the 198 patients who underwent HCT (43 percent) and the 427 patients who received chemotherapy alone (41 percent), the effect of HCT on survival appeared to differ greatly according to karyotype risk subgroup. As an example, children younger than six years with precursor B cell ALL without MLL rearrangement (ie, low risk factors) appeared to have higher survival rates when treated with chemotherapy alone rather than HCT (73 versus 59 percent). In contrast, older children and those with elevated WBC, T cell ALL, and additional cytogenetic risk factors had higher survival rates with a matched related donor HCT rather than chemotherapy alone (59 versus 35 percent).",
"   </p>",
"   <p>",
"    It is not known how these estimated survival rates may be affected by changes in standard therapy that have evolved since the time these patients were treated. In particular, the addition of BCR-ABL tyrosine kinase inhibitors to the standard treatment of BCR-ABL1 positive ALL has improved median survival times in this subset of patients, an effect that may not be reflected in this patient population.",
"   </p>",
"   <p>",
"    While smaller, the following studies provide data regarding the outcomes of patients with induction failure enrolled on prospective trials:",
"   </p>",
"   <p>",
"    In one study of 774 children with ALL (including T cell ALL) from the United States, 23 had persistent leukemia after completion of induction therapy and were treated with additional induction chemotherapy. Although 21 patients eventually achieved CR, their five-year event-free survival (EFS) was only 16 percent (95% CI: 0-31 percent) regardless of management regimen, compared to 82 percent (95% CI: 79-86 percent) in the group that achieved remission within one month and 79 percent (95% CI: 70-87 percent) in those who had protracted hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a French study of 1395 children with ALL, a multivariate analysis identified three groups based upon their risk for induction failure [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/27\">",
"     27",
"    </a>",
"    ]. The intermediate- and high-risk groups had a 7.4- and 28.4-fold increase risk of induction failure compared to the low-risk group. The groups were treated based upon Berlin-Frankfurt-Munster study (BFM) protocols. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The low-risk group (n = 1080) had precursor B cell ALL without the \"Philadelphia\" translocation, t(9;22).",
"     </li>",
"     <li>",
"      The intermediate-risk group (n = 124) had T cell ALL and mediastinal involvement.",
"     </li>",
"     <li>",
"      The high-risk group either had precursor B cell ALL with the Philadelphia translocation t(9;22) (n = 39), or had T cell ALL without mediastinal involvement (n = 53).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, 53 patients failed induction therapy. With salvage therapy, 43 patients entered complete remission, 39 after one second-line course of chemotherapy and four who required more than one course. Both the overall survival rate and the EFS for the 53 patients who failed induction therapy compared to those who responded to therapy were markedly lower (30 and 27 percent versus 85 and 75 percent, respectively). In addition, the observation that patients with T cell ALL without mediastinal mass were more likely to have induction failure than T cell ALL patients with a mediastinal mass remains to be substantiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon, some children with ALL experience significant adverse effects during induction chemotherapy. Toxicity can result from the chemotherapeutic agents or from the rapid elimination of a large tumor burden (ie, tumor lysis syndrome). Life-threatening adverse effects of induction therapy include tumor lysis syndrome, thrombosis, bleeding, and infection. Other acute side effects include mucositis, pancreatitis, and hyperglycemia. Late effects of chemotherapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Late effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Tumor lysis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute tumor lysis syndrome is the term applied to a group of metabolic complications that may occur after the treatment of neoplastic disorders. The findings that may be seen include hyperphosphatemia, hypocalcemia (caused by precipitation of calcium phosphate), hyperuricemia, hyperkalemia, and acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=see_link\">",
"     \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid leukemic cell lysis after chemotherapy can cause over-production and over-excretion of uric acid. The precipitation of uric acid in the tubules can lead to oliguric or anuric renal failure known as uric acid nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 328 children with ALL, the following four factors were identified as independent predictors of tumor lysis syndrome on multivariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;10 years",
"     </li>",
"     <li>",
"      Splenomegaly",
"     </li>",
"     <li>",
"      Mediastinal mass",
"     </li>",
"     <li>",
"      Initial white blood cell count",
"      <span class=\"nowrap\">",
"       &gt;20,000/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Absence of all four of these risk factors indicated a low risk for development of tumor lysis syndrome, with a negative predictive value of 98 percent and a sensitivity of 96 percent.",
"   </p>",
"   <p>",
"    Prophylactic regimens to prevent acute uric acid nephropathy in children with ALL include the administration of medications to reduce the production of uric acid (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/3/24629?source=see_link\">",
"     allopurinol",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/5/23636?source=see_link\">",
"     rasburicase",
"    </a>",
"    , a recombinant uricase that catalyzes oxidation of uric acid to the much more soluble compound allantoin), and aggressive intravenous hydration. Hemodialysis may be necessary to remove excess circulating uric acid and phosphate in patients who develop acute renal failure and in whom adequate diuresis cannot be achieved. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712037#H21712037\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Clinical impact of TLS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for hemodialysis in children with tumor-induced uric acid nephropathy has decreased with the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/5/23636?source=see_link\">",
"     rasburicase",
"    </a>",
"    , the enzyme that catalyzes oxidation of uric acid to the much more soluble compound allantoin [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Uricase (Elitek, rasburicase) was approved by the FDA for the \"initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid\" [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=see_link&amp;anchor=H21712072#H21712072\">",
"     \"Tumor lysis syndrome: Prevention and treatment\", section on 'Rasburicase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse effects of uricase include allergic reactions, including anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/36\">",
"     36",
"    </a>",
"    ], hemolysis, hemoglobinuria, methemoglobinemia, and interference with uric acid measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. This agent is contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency because it can cause severe hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic events, including intracranial dural sinus thrombosis with hemorrhage, deep vein thrombosis, and pulmonary embolism, have been reported with induction chemotherapy regimens for ALL that include L-asparaginase [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. The incidence of thrombotic complications among children with ALL receiving L-asparaginase has varied among studies from as low as 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/38\">",
"     38",
"    </a>",
"    ] to as high as 11 percent in children with other prothrombotic risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2006 meta-analysis of 1752 children with ALL reported that 5.2 percent of patients developed a thrombosis at some time during treatment (ie, from the start of induction through the end of maintenance) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/42\">",
"     42",
"    </a>",
"    ]. Most (83 percent) of these events occurred during induction therapy. The following four risk factors for thrombosis were identified in this population:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment with asparaginase",
"     </li>",
"     <li>",
"      Concomitant use of steroids",
"     </li>",
"     <li>",
"      Thrombophilic genetic abnormalities",
"     </li>",
"     <li>",
"      Presence of central venous lines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a European study, these risk factors were used to develop a predictive model for identifying children with ALL at the highest risk of thrombosis during induction with asparaginase-based therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis of 336 consecutively recruited children with ALL treated on different Berlin-Frankfurt-Munster (BFM) study protocols found a lower incidence of thromboembolism when L-asparaginase was used in conjunction with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    rather than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    (1.8 versus 10.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/44\">",
"     44",
"    </a>",
"    ]. The incidence of prothrombotic risk factors was the same in both groups. Forty-six percent of the children in the prednisone group who had a prothrombotic risk factor experienced thromboembolism, whereas no child in the dexamethasone-treated group with such a risk factor experienced this complication. Thus, the combination that puts the child at risk may be four-fold: use of asparaginase, presence of a prothrombotic risk factor, including the use of central venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/45\">",
"     45",
"    </a>",
"    ], and use of prednisone and an anthracycline [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/42\">",
"     42",
"    </a>",
"    ]. The results of this study, limited by the small number of patients (56) in the dexamethasone treatment group, bear further scrutiny in prospective trials with larger numbers of patients.",
"   </p>",
"   <p>",
"    Asparaginase depletes plasma asparagine, thereby inhibiting protein synthesis in leukemic cells and the synthesis of many plasma proteins. The latter effect causes deficiencies of albumin, thyroxine-binding globulin, and various coagulation proteins, including prothrombin, factors V, VII, VIII, IX, X, XI, fibrinogen, antithrombin, protein C, protein S, and plasminogen [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. These deficiencies result in prolongation of the prothrombin time, activated partial thromboplastin time (aPTT), thrombin time, and hypofibrinogenemia, with levels often less than 100",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    These coagulation abnormalities resolve within one to two weeks after cessation of the drug. PEG-asparaginase and L-asparaginase appear to have equivalent risk of severe thrombosis. One study demonstrated that the risk of CNS thrombosis with PEG-asparaginase was 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=see_link&amp;anchor=H3#H3\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\", section on 'L-asparaginase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhage in children with ALL usually is caused by thrombocytopenia. Patients who have platelet counts",
"    <span class=\"nowrap\">",
"     &lt;10,000/microL",
"    </span>",
"    are at greatest risk. Children with thrombocytopenia typically have bleeding from the skin or mucus membranes; significant visceral bleeding is unusual. Intracranial hemorrhages are rare but life-threatening events. Treatment or prevention of such bleeding is provided by transfusion of platelets (",
"    <a class=\"graphic graphic_table graphicRef52206 \" href=\"UTD.htm?11/29/11741\">",
"     table 2",
"    </a>",
"    ). The American Society of Clinical Oncology (ASCO) guidelines presented in the tables were developed for adults; more conservative recommendations are often used for children. Recommendations vary among institutions; many transfuse children who have chemotherapy-associated myelosuppression when blood platelet counts are",
"    <span class=\"nowrap\">",
"     &lt;20,000/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558395349#H558395349\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Leukemia and chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who require prolonged antibiotic therapy may develop bleeding secondary to a vitamin-K dependent coagulopathy. Patients with an elevated prothrombin time (PT) are treated with oral or intravenous vitamin K (2.5 to 5.0 mg PO per day; or if bleeding, 1 to 2 mg IV as a single dose). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=see_link&amp;anchor=H18#H18\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\", section on 'Hematologic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with newly diagnosed ALL may be neutropenic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphopenic at the time of diagnosis and may develop further myelosuppression because of chemotherapy. These children are more susceptible to development of systemic bacterial, fungal, and viral infections (eg, varicella-zoster, herpes simplex virus).",
"   </p>",
"   <p>",
"    As an example, in a retrospective review of 425 children who received induction therapy for ALL between 1997 and 2006 at a single tertiary Canadian center, 20 percent of all patients experienced at least one documented infection [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/50\">",
"     50",
"    </a>",
"    ]. Neutropenia was almost twice as common in those who developed infections compared to those without infection. Patients with pre-existing conditions (Down syndrome, congenital heart disease, pre-existing immunodeficiency syndromes) were also at increased risk of infections. The 85 infections included 65 bacterial, 15 viral, and 5 fungal infections. Infectious mortality was minimal",
"    <span class=\"nowrap\">",
"     (3/425,",
"    </span>",
"    1 percent) and included deaths from both fungal (Candida albicans) and bacterial (Bacillus cereus) infections.",
"   </p>",
"   <p>",
"    Because these infections are potentially life-threatening in any phase of therapy, fever in children who are receiving chemotherapy must be evaluated and treated aggressively. The use of prophylactic antimicrobial therapy is recommended, but the specific therapy varies by circumstance and institution. For example, the use of an antimicrobial (sulfamethoxazole-trimethoprim,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/31/34288?source=see_link\">",
"     dapsone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37734?source=see_link\">",
"     pentamidine",
"    </a>",
"    ) Pneumocystis carinii pneumonitis prophylaxis is almost universal in the management of patients receiving chemotherapy, while the administration of antifungals and anti viral agents is more individualized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link\">",
"     \"Fever in children with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of colony-stimulating factors (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    and granulocyte macrophage colony-stimulating factor) to prevent or manage infectious complications during ALL induction has not been well studied. In one randomized, crossover study in 287 children with high-risk ALL, prophylactic use of granulocyte colony-stimulating factor shortened periods of neutropenia, but did not reduce rates of febrile neutropenia, serious infections, or the need for hospitalization; overall survival at six years was not affected [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/51\">",
"     51",
"    </a>",
"    ]. A systematic review has come to similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some chemotherapy and supportive medications, such as asparaginase, the epipodophyllotoxins (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23686?source=see_link\">",
"     teniposide",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/17/41240?source=see_link\">",
"     etoposide",
"    </a>",
"    ), and uricase can cause significant allergic reactions, including anaphylaxis. Medications used to treat anaphylaxis should be readily available when these drugs are administered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H45#H45\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'L-asparaginase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5181929\">",
"    <span class=\"h3\">",
"     HPA axis suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of daily corticosteroids during induction therapy results in suppression of the hypothalamic-pituitary-adrenal (HPA) axis in nearly all patients. Because nearly all patients experienced adrenal insufficiency during the first days after cessation of glucocorticoid treatment, it is recommended that children with infections, trauma, or surgery occurring shortly after induction be treated with glucocorticoid replacement. While the majority recovers HPA axis function within a few weeks after corticosteroid cessation, HPA axis suppression lasted up to 34 weeks in one analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/53\">",
"     53",
"    </a>",
"    ]. For this reason, glucocorticoid replacement following trauma, infection, or surgery should be considered on a case-by-case basis for children with ALL during consolidation treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link&amp;anchor=H5#H5\">",
"     \"Glucocorticoid withdrawal\", section on 'Hypothalamic-pituitary-adrenal axis suppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17255?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CNS PREVENTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemic involvement of the central nervous system (CNS) at the time of diagnosis is an uncommon finding, occurring in fewer than 5 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/54\">",
"     54",
"    </a>",
"    ]. However, before the use of preventive CNS therapy, up to 80 percent of children with ALL who were in complete bone marrow remission relapsed with \"leukemic meningitis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The routine use of preventive CNS therapy is a major therapeutic advance in the treatment of childhood ALL. CNS treatment usually begins during the induction phase and continues throughout the remainder of the treatment regimen.",
"   </p>",
"   <p>",
"    Craniospinal radiotherapy or cranial radiotherapy, once considered the standard of care, was effective in preventing CNS leukemia but was associated with significant toxicity, such as cognitive impairment and altered white matter development [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Approximately 50 percent of children treated with 24 Gy craniospinal radiation developed CNS changes detected by MRI (atrophy, leukoencephalopathy, calcifications, or grey matter abnormalities), secondary brain tumors, and had decreased performance on neuropsychological testing [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'CNS and cognition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Brain tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, craniospinal radiotherapy has been replaced by intrathecal chemotherapy in several CNS preventive therapy protocols. Outcome data from these protocols have demonstrated that replacement of craniospinal radiotherapy with frequent administrations of intrathecal therapy does not compromise event-free or overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/60-65\">",
"     60-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a randomized trial from the Dana-Farber Cancer Institute ALL Consortium, in which children with standard-risk ALL were assigned to receive either intensive triple intrathecal chemotherapy",
"    <span class=\"nowrap\">",
"     (",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=see_link\">",
"      cytarabine",
"     </a>",
"     /",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"      methotrexate",
"     </a>",
"     /",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"      hydrocortisone",
"     </a>",
"     ),",
"    </span>",
"    or 1800 cGy cranial radiation with less frequent intrathecal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/60\">",
"     60",
"    </a>",
"    ]. There was no difference between the two groups in five-year, event-free survival (EFS) (83 versus 86 percent) or the rate of CNS relapse (6 percent in each group). A subsequent analysis of the neuropsychological outcomes found that cognitive function was in the average range in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/61\">",
"     61",
"    </a>",
"    ]. However, children who received 18 Gy or more of cranial radiotherapy had less fluent language output and were less effective at modulating their behavior according to their parents. Given the similar rates of efficacy, the authors concluded that intensive intrathecal therapy was preferable to regimens that include cranial radiation therapy.",
"   </p>",
"   <p>",
"    A subsequent study evaluated the efficacy of regimens without cranial irradiation in 498 consecutive children (age range 1 to 18 years) with ALL who were treated with triple intrathecal therapy, and intensified systemic chemotherapy based upon disease risk stratification after remission induction [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/62\">",
"     62",
"    </a>",
"    ]. Intrathecal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=see_link\">",
"     cytarabine",
"    </a>",
"    was initially administered on day 1 of remission induction and followed by subsequent triple intrathecal chemotherapy",
"    <span class=\"nowrap\">",
"     (cytarabine/",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"      methotrexate",
"     </a>",
"     /",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"      hydrocortisone",
"     </a>",
"     ).",
"    </span>",
"    The number of intrathecal treatments ranged from 13 to 25 and was based upon disease risk stratification and patient characteristics, including CNS status of disease.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The five-year event-free and overall survival rates were 86 and 94 percent.",
"     </li>",
"     <li>",
"      The five-year cumulative risk was 3.9 percent any CNS relapse (isolated, and combined CNS and hematologic relapse) and 2.7 percent for isolated CNS relapse.",
"     </li>",
"     <li>",
"      The five-year remission rate was significantly higher in the 71 patients who would have previously received prophylactic cranial irradiation than 56 historical controls who received cranial irradiation (91 versus 73 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of these two studies demonstrate that intrathecal therapy provides similar event-free and overall survival in a cohort of children with ALL.",
"   </p>",
"   <p>",
"    However, it should be noted that all recommendations for CNS preventive therapies should be evaluated in the context of the related systemic therapy regimens and should not be applied to other treatments without more evidence. Some current protocols continue to incorporate lower dose cranial radiation (&lt;1800 cGy) for patients where CNS leukemia is felt to be a significant risk factor.",
"   </p>",
"   <p>",
"    Further studies are also needed to better define whether there is any role for CNS radiation in children who have CNS involvement (either at the time of diagnosis or at CNS relapse), or in patients with high-risk ALL.",
"   </p>",
"   <p>",
"    Although the incidence of neurotoxicity is reduced by intrathecal therapy, it is not eliminated and remains a significant risk. Intrathecal chemotherapy (with either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    alone, or methotrexate combined with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=see_link\">",
"     cytarabine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    ) is associated with acute neurotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/66\">",
"     66",
"    </a>",
"    ], including seizures and leukoencephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CONSOLIDATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consolidation or intensification therapy is the second phase of ALL treatment and is initiated soon after attainment of CR. Ongoing treatment is required because small numbers of leukemic lymphoblasts (referred to as minimal residual disease [MRD]) remain in the bone marrow despite histologic evidence of CR after induction therapy. In such cases, relapse occurs quickly if therapy is not continued.",
"   </p>",
"   <p>",
"    The goal of post-induction chemotherapy is to prevent leukemic regrowth, reduce residual tumor burden, and prevent the emergence of drug-resistance in the remaining leukemic cells.",
"   </p>",
"   <p>",
"    Consolidation therapy usually lasts from four to six months. It commonly involves the use of several different drug combinations and drugs with mechanisms of action that differ from those used during the induction phase. Regimens often include the following drugs administered according to a variety of schedules to maximize drug synergy and minimize the development of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37655?source=see_link\">",
"       Cytarabine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"       Methotrexate",
"      </a>",
"     </li>",
"     <li>",
"      Anthracyclines (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/19/31029?source=see_link\">",
"       daunorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20711?source=see_link\">",
"       doxorubicin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alkylating agents (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/33/11800?source=see_link\">",
"       ifosfamide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An epipodophyllotoxin (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/8/23686?source=see_link\">",
"       teniposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/17/41240?source=see_link\">",
"       etoposide",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intensification of therapeutic regimens has been adjusted based upon the patient's risk of poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/69\">",
"     69",
"    </a>",
"    ]. This has allowed a reduction of intensification therapy for patients with good prognosis while providing more intensive treatment for those in the high-risk group with the goal of improving survival. The MRD status is one of the most important predictor of disease-free and overall survival. Patients with detectable MRD have an increased risk of relapse after conventional therapy. As a result, ongoing trials are evaluating the escalation of consolidation therapy intensity in MRD positive cases and the reduction of therapy intensity in MRD negative cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\", section on 'MRD in children'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37753?source=see_link&amp;anchor=H14#H14\">",
"     \"Risk group stratification and prognosis for acute lymphoblastic leukemia in children\", section on 'Minimal residual disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improved survival also has been gained with the addition of one or more pulses of more intensive therapy during early post-induction [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/8,70-72\">",
"     8,70-72",
"    </a>",
"    ], an approach known as delayed intensification [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/8,70,71\">",
"     8,70,71",
"    </a>",
"    ]. Delayed intensification involves the administration of a five- to six-week \"pulse\" of intensive, multi-agent chemotherapy similar to that administered during induction. This pulse is given once [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/8,70,73\">",
"     8,70,73",
"    </a>",
"    ] or twice [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/71,72\">",
"     71,72",
"    </a>",
"    ] during the first six months of post-remission therapy, with a less intensive period of therapy immediately after induction and between the pulses.",
"   </p>",
"   <p>",
"    The intensity of this phase of therapy is commensurate with the patient's risk grouping. As a general rule, the higher the risk for treatment failure, the more aggressive the intensification therapy plan. This was demonstrated in a Children's Oncology Group trial of 1299 patients with higher risk ALL that had rapid marrow response to induction therapy. This study demonstrated that a more intensive delayed intensification regimen resulted in improved event-free survival and overall survival at five years compared with either standard therapy or longer duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/74\">",
"     74",
"    </a>",
"    ]. Although some patients with high-risk disease benefit from the two delayed intensification regimens (DDI), the benefit for patients with standard risk disease is less certain as this group has an improvement in EFS but not overall survival following DDI regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/71,74\">",
"     71,74",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Selected patients with high-risk disease have an increased incidence of relapse during intensification chemotherapy (eg, Philadelphia chromosome positive ALL, severe hypodiploid ALL (less than 46 chromosomes), infants with ALL, and those who have failed initial induction therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/26,75-77\">",
"     26,75-77",
"    </a>",
"    ]. These patients are candidates for receiving hematopoietic cell transplantation (HCT) during first remission. However, it remains unclear whether HCT offers a better overall survival or five-year, disease-free survival than intense chemotherapy in high-risk patients, especially in patients with the Philadelphia gene translocation receiving tyrosine kinase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the intensification phase of chemotherapy most patients still have significant myelo- and immunosuppression. They remain at risk for bacterial, viral, and fungal infections during periods of neutropenia, and fevers should be aggressively treated. Patients can also experience many of the same complications (eg, infection) seen during induction therapy, although these are usually less common.",
"   </p>",
"   <p>",
"    More aggressive treatment regimens involving multiple chemotherapeutic agents place high-risk patients at risk for additional complications. High-risk ALL patients have an increased risk of secondary cancers (associated with epipodophyllotoxins or radiation) and decreased fertility (a risk for adolescents receiving alkylating agents). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Late effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall treatment duration for most children with ALL is 24 to 36 months. After completion of the consolidation or intensification phase of therapy, patients often receive a less intensive continuation regimen using daily oral 6-mercaptopurine (6-MP) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/80\">",
"     80",
"    </a>",
"    ] and weekly",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    with periodic intrathecal therapy.",
"   </p>",
"   <p>",
"    Although, it is unclear whether all patients with ALL benefit from maintenance therapy that includes a combination of pulse therapy",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    and steroids in addition to a daily regimen of 6-MP and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"     methotrexate",
"    </a>",
"    , patients with standard-risk ALL who receive this combination appear to have a more favorable long-term outcome than those treated with only 6-MP and methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. The optimal time interval for vincristine plus steroid pulses is also unclear; this question is currently being studied in a large prospective COG trial (AALL0832). Patients with high-risk ALL, including those with T cell ALL or infant ALL, may require a more aggressive continuation regimen with additional drug combinations.",
"   </p>",
"   <p>",
"    During maintenance therapy, patients remain at risk for infection. Fever in children who are receiving chemotherapy must be evaluated and treated aggressively, especially if the patient is either neutropenic or has a central venous access device.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/31/34288?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37734?source=see_link\">",
"     pentamidine",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/19/8501?source=see_link\">",
"     atovaquone",
"    </a>",
"    prophylaxis is used to prevent Pneumocystis carinii pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/83\">",
"     83",
"    </a>",
"    ]. Children and their household contacts should not be given live-virus immunization while receiving chemotherapy. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Immunizations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PRIMARY CARE CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For practical reasons, most patients with ALL remain under the primary care of their oncologists during the induction and consolidation portions of their chemotherapy. Once a patient enters the less intensive maintenance therapy, however, the primary care provider (PCP) can often provide routine medical care with scheduled visits to the oncologist for chemotherapy, particularly if the family lives some distance from the oncology treatment center. When ALL therapy is complete, the PCP resumes primary care for the patient, including visits for health maintenance and acute illnesses.",
"   </p>",
"   <p>",
"    During and after completion of chemotherapy, the oncologist usually coordinates follow-up physical examinations, procedures, and imaging studies. The PCP, however, plays an important role in encouraging patients to return to their oncologists for scheduled visits and follow-up studies. Communication between the PCP and the oncologist is critical throughout the treatment process.",
"   </p>",
"   <p>",
"    The purpose of frequent follow-up visits after the cessation of chemotherapy is to examine ALL survivors for disease recurrence and to screen them for the long-term side effects mentioned below. Patients are closely followed for several years after completion of chemotherapy. Although there is no standard follow-up frequency, patients are typically followed by their oncologist monthly for the first year after therapy completion, and then at less frequent intervals for the next two to four years. After three to five years, patients are followed on an annual basis with a focus on long-term survivor issues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Late effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with vaccine administration in children undergoing cancer treatment is limited and there are little published data regarding response to specific vaccines in patients receiving immunosuppressive chemotherapy. Data from HIV-infected infants indicates that the risk of adverse events after immunization is low [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ALL should receive only inactive immunizations during chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/84\">",
"     84",
"    </a>",
"    ]. Live-virus vaccines such as MMR and oral poliovirus are contraindicated. After completion of chemotherapy, the patient should receive any missed vaccinations, including MMR and varicella.",
"   </p>",
"   <p>",
"    Cancer patients have a variable response to the immunizations received while immunosuppressed. In addition, children with ALL whose immunizations were up-to-date at the time of diagnosis may fail to maintain protective antibody titers after completion of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. For this reason, it is recommended that antibody titers be checked three to six months after the completion of chemotherapy. Children can be revaccinated at that time if they have low antibody titers [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/84,87\">",
"     84,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients whose therapy included hematopoietic cell transplantation often repeat their complete immunization series beginning approximately one year after transplantation. Testing of immune function in vitro may provide evidence for safe immunization timing in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Varicella vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the variability of chemotherapy regimens and the current decreasing incidence of varicella, the American Academy of Pediatrics does not recommend routine varicella vaccination for children actively receiving chemotherapy. If varicella vaccination is performed in a child in remission without evidence of immunity, it should be undertaken with expert guidance and with the availability of antiviral therapy should complications occur [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Influenza vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influenza vaccine is usually administered to children with ALL. Some institutions defer administration until three to four weeks after chemotherapy or administer the vaccine only if the absolute neutrophil count (ANC) exceeds 1000",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Monitoring for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    signs and symptoms of ALL relapse typically are similar to those of initial presentation. They include fever, malaise, bleeding, and bone pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ALL relapse most commonly occurs in the bone marrow and usually presents with persistent peripheral blood cytopenias. Health care providers should pay close attention to persistent abnormal blood counts in the ALL survivor. Prompt referral for bone marrow examination is warranted if there is suppression of more than one cell line or unexplained suppression of one cell line that persists for longer than three to four weeks.",
"   </p>",
"   <p>",
"    The second most common site of ALL relapse is the central nervous system (CNS). However, the frequency of CNS relapse has diminished with the advent of intrathecal therapy for newly-diagnosed ALL. CNS relapse may manifest with symptoms of increased intracranial pressure (headache, morning vomiting), nuchal rigidity, focal neurologic findings (particularly cranial nerve palsies), or papilledema.",
"   </p>",
"   <p>",
"    Testicular relapse is uncommon (&lt;5 percent) with current treatment regimens. Testicular relapse often presents as unilateral, painless testicular enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/89\">",
"     89",
"    </a>",
"    ]. Diagnosis is made by testicular biopsy. Bilateral biopsies are indicated if testicular relapse is suspected, since leukemic cells are frequently found in the contralateral testis [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leukemic infiltrates rarely recur in other extramedullary sites, including the ovary, kidney, skin, and eye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29267332\">",
"    <span class=\"h1\">",
"     RELAPSED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 to 25 percent of children with ALL fail initial treatment. Most of these failures occur in the bone marrow and a few in extramedullary sites, primarily the central nervous system (CNS), and, rarely, in other sites such as the testicles or lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/91\">",
"     91",
"    </a>",
"    ]. The outcome for these patients is guarded when compared with those without recurrence. Relapse following ALL therapy remains the second most common cause of cancer-related death in children. The vast majority of relapses occur within 2.5 years from diagnosis. For patients with T cell ALL, recurrences more than 2.5 years from diagnosis may represent a second leukemia rather than a relapse of the original leukemia. Late relapses in children with pre-B ALL, however, appear to represent clonal evolution of the original disease [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with relapsed ALL require aggressive reinduction therapy and intensification, often using agents not administered in the original treatment protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/93\">",
"     93",
"    </a>",
"    ]. Patients with high-risk ALL, such as those over 10 years of age or those with high initial WBC counts, often do not respond well to treatment with additional chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/94\">",
"     94",
"    </a>",
"    ]. Patients who have CNS or testicular relapse require radiation therapy at some point during the rescue therapy program [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following agents have been used for the treatment of relapsed ALL (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\", section on 'Remission induction'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/19/20789?source=see_link\">",
"       Nelarabine",
"      </a>",
"      (Arranon), a prodrug converted in vivo to ara-GTP especially in T cells, has shown efficacy as a single agent for the treatment of relapsed or resistant T cell ALL in children and adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\", section on 'Nelarabine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/15/29941?source=see_link\">",
"       Clofarabine",
"      </a>",
"      (Clolar) is a nucleoside analogue structurally related to both",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/28/42438?source=see_link\">",
"       fludarabine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/10/11430?source=see_link\">",
"       cladribine",
"      </a>",
"      . Clofarabine disrupts nucleotide metabolism by inhibiting nucleoside incorporation into DNA, preventing nucleotide pool recycling by inhibiting the enzyme ribonucleotide reductase, and disrupting mitochondrial integrity, which results in the release of mitochondrial proteins that trigger apoptosis. Clofarabine has been approved by the FDA for treatment of ALL in relapse, and can be seen as a potential \"bridge to transplant\" since half of the responding acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients were able to receive a subsequent stem cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although patients in first relapse usually attain a second remission with induction chemotherapy, they often relapse after short periods despite aggressive treatment. These patients are candidates for hematopoietic cell transplantation (HCT) once they have attained second remission [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29267339\">",
"    <span class=\"h2\">",
"     Survival after relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival rate of patients who relapse is dependent upon a variety of risk factors. This was illustrated in a retrospective review of 1961 patients with a relapse from a cohort of 9585 enrolled children with ALL in the Children's Oncology Group clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/99\">",
"     99",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The strongest predictor of survival was the time of relapse from initial diagnosis. Patients who relapsed less than 18 months after diagnosis had a poor outcome, with a five-year survival rate of about 21 percent.",
"     </li>",
"     <li>",
"      Five-year survival rates were higher in patients with isolated CNS relapse compared with isolated or concurrent BM relapse (59, 24, and 39 percent, respectively).",
"     </li>",
"     <li>",
"      Patients with high-risk disease had a lower survival rate than those with lower risk disease. The lowest survival rate was in patients with high-risk disease who relapsed before 18 months after diagnosis (15 percent).",
"     </li>",
"     <li>",
"      After adjusting for site and time of relapse, multivariate analysis of 1391 patients demonstrated that older patients (greater than 10 years of age), presence of CNS disease at diagnosis, male gender, and T cell disease were associated with poor survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above, important predictors of survival include the site and timing of relapse and the treatment regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/94,99-101\">",
"     94,99-101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Site of relapse &mdash; The long-term survival in ALL patients with bone marrow relapse varies from 5 to 60 percent and depends upon the additional treatment for relapse, standard versus high-risk initial disease status, and time to relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/94,100,101\">",
"       94,100,101",
"      </a>",
"      ]. Overall, children who have isolated CNS relapse fare better than those who have bone marrow relapse, with a five- to 10-year EFS of 54 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/99,102\">",
"       99,102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Time to relapse &mdash; The longer duration between relapse and the time of diagnosis, the better the survival rate [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/94,99\">",
"       94,99",
"      </a>",
"      ]. Patients who relapse after completion of chemotherapy fare better than those who relapse while still on therapy. Patients with high-risk disease often relapse while still receiving chemotherapy. For these patients, survival rates improve with increased duration of first remission.",
"      <br/>",
"      <br/>",
"      Patients with low-risk disease tend to relapse after the completion of chemotherapy, often after a prolonged time in remission. The response to a second treatment program correlates directly with the length of first remission [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/103,104\">",
"       103,104",
"      </a>",
"      ]. As an example, in the experience of the Children's Cancer Group, rates of survival after isolated bone marrow relapse at &le;17 months, 18 to 35 months, and &gt;36 months were 6, 11, and 43 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/103\">",
"       103",
"      </a>",
"      ]. Although HCT appears to be more successful than chemotherapy for patients who relapse early (ie, &lt;36 months), its role in the management of late failures is less well defined [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/97,105\">",
"       97,105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Phase of treatment &mdash; Patients in the maintenance portion of their chemotherapy who are receiving",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/32/13833?source=see_link\">",
"       methotrexate",
"      </a>",
"      and 6-mercaptopurine can be successfully treated with more aggressive chemotherapy regimens. Patients who relapse while receiving induction or consolidation chemotherapy, however, usually respond poorly to additional chemotherapy. Following reinduction, these patients are often considered for HCT.",
"     </li>",
"     <li>",
"      Treatment regimen &mdash; Outcome also varies by the treatment regimen used at relapse. As an example, a multicenter phase III randomized trial compared",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/57/33685?source=see_link\">",
"       idarubicin",
"      </a>",
"      with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/7/12407?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      in 216 children with relapsed ALL [",
"      <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/106\">",
"       106",
"      </a>",
"      ]. Consolidation after this second induction was stratified based upon risk. Although mitoxantrone did not result in an increase in CR rate after induction, mitoxantrone resulted in significantly higher rates of progression-free (65 versus 36 percent), and overall (69 versus 45 percent) survival at three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis at the time of relapse, however, does not appear to be related to the intensity of the initial therapy regimen used in current treatment protocols or the age at transplantation (ie, patients &lt;14 years versus 14 to 18 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. As an example, a report from the Children&rsquo;s Oncology Group included 256 evaluable children with relapsed ALL whose initial ALL treatment was randomly assigned to include either a standard intensity postinduction regimen or an augmented intensity postinduction regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?31/6/31850/abstract/107\">",
"     107",
"    </a>",
"    ]. Three-year survival rates after relapse were similar in the two treatment groups (36 versus 39 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/40/24194?source=see_link\">",
"       \"Patient information: Leukemia in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most children with newly diagnosed ALL are treated on research protocols with risk stratification based upon prognostic indicators available at the time of presentation (",
"      <a class=\"graphic graphic_table graphicRef71649 \" href=\"UTD.htm?0/35/574\">",
"       table 1",
"      </a>",
"      ). Such research protocols have helped to standardize treatment, improve survival rates, and reduce the long-term complications of therapy.",
"     </li>",
"     <li>",
"      Although cure rates approach and may surpass 80 percent in many studies, significant challenges remain, particularly for children with adverse prognostic indicators such as the t(9;22) Philadelphia translocation or relapsed ALL. Novel therapies for these patients and the implementation of new techniques to further refine risk stratification should further improve survival rates in childhood ALL. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because they are at risk for long-term complications, it is crucial that survivors of childhood ALL continue regular follow-up with their oncologists after the cessation of chemotherapy. Long-term complications are related to the type and intensity of the treatment regimen. Patients with high-risk ALL receive more aggressive chemotherapy and are at greater for acute and chronic adverse effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=see_link\">",
"       \"Overview of the outcome of acute lymphoblastic leukemia in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEER Cancer Statistic Review, 1973-1999. National Cancer Institute, Bethesda, MD, 2000. p.467.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/2\">",
"      Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104:2690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/3\">",
"      Gatta G, Capocaccia R, Stiller C, et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005; 23:3742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/4\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/5\">",
"      Rubnitz JE, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer 2004; 101:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/6\">",
"      Boissel N, Auclerc MF, Lh&eacute;ritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/7\">",
"      Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-M&uuml;nster. Leukemia 2000; 14:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/8\">",
"      Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000; 14:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/9\">",
"      Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/10\">",
"      Kamps WA, Veerman AJ, van Wering ER, et al. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991. Leukemia 2000; 14:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/11\">",
"      Maloney KW, Shuster JJ, Murphy S, et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000; 14:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/12\">",
"      Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/13\">",
"      Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000; 14:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/14\">",
"      Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007; 12:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/15\">",
"      Rives S, Estella J, G&oacute;mez P, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol 2011; 154:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/16\">",
"      Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27:5175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/17\">",
"      Ribera JM, Oriol A, Gonz&aacute;lez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010; 95:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/18\">",
"      Fuster JL, Berm&uacute;dez M, Galera A, et al. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2007; 92:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/19\">",
"      Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001; 113:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/20\">",
"      Ribera JM, Ortega JJ, Oriol A, et al. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 2002; 87:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/21\">",
"      Visser JH, Wessels G, Hesseling PB, et al. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001; 18:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/22\">",
"      Coustan-Smith E, Ribeiro RC, Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006; 108:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/23\">",
"      Sutton R, Venn NC, Tolisano J, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol 2009; 146:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/24\">",
"      Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005; 366:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/25\">",
"      Cav&eacute; H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/26\">",
"      Silverman LB, Gelber RD, Young ML, et al. Induction failure in acute lymphoblastic leukemia of childhood. Cancer 1999; 85:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/27\">",
"      Oudot C, Auclerc MF, Levy V, et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 2008; 26:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/28\">",
"      Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012; 366:1371.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD. Pathophysiology of Renal Disease, 2nd ed, McGraw-Hill, New York 1987. p.418.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/30\">",
"      Kjellstrand CM, Cambell DC 2nd, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med 1974; 133:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/31\">",
"      Truong TH, Beyene J, Hitzler J, et al. Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome. Cancer 2007; 110:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/32\">",
"      Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 2001; 19:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/33\">",
"      Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97:2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/34\">",
"      Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001; 38:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/35\">",
"      Sanofi Elitek for uric acid management will launch by mid-August. \"The Pink Sheet\", July 22, 2002. F-D-C Reports 2002; 64:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/36\">",
"      Montagnac R, Schillinger F. [Anaphylactic complication tied to intravenous injection of urate oxidase in a dialysis patient]. Nephrologie 1990; 11:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/37\">",
"      Priest JR, Ramsay NK, Latchaw RE, et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 1980; 46:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/38\">",
"      Priest JR, Ramsay NK, Steinherz PG, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982; 100:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/39\">",
"      Steinherz PG, Miller LP, Ghavimi F, et al. Dural sinus thrombosis in children with acute lymphoblastic leukemia. JAMA 1981; 246:2837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/40\">",
"      Athale UH, Siciliano SA, Crowther M, et al. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005; 129:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/41\">",
"      Nowak-G&ouml;ttl U, Heinecke A, von Kries R, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001; 103:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/42\">",
"      Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/43\">",
"      Mitchell L, Lambers M, Flege S, et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 2010; 115:4999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/44\">",
"      Nowak-G&ouml;ttl U, Ahlke E, Fleischhack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003; 101:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/45\">",
"      Korte W, Greiner J. PARKAA paves the way. Thromb Haemost 2003; 90:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/46\">",
"      Bezeaud A, Drouet L, Leverger G, et al. Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. J Pediatr 1986; 108:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/47\">",
"      Buchanan GR, Holtkamp CA. Reduced antithrombin III levels during L-asparaginase therapy. Med Pediatr Oncol 1980; 8:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/48\">",
"      Conard J, Horellou MH, Van Dreden P, et al. Decrease in protein C in L-asparaginase-treated patients. Br J Haematol 1985; 59:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/49\">",
"      Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/50\">",
"      Afzal S, Ethier MC, Dupuis LL, et al. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J 2009; 28:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/51\">",
"      Heath JA, Steinherz PG, Altman A, et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. J Clin Oncol 2003; 21:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/52\">",
"      Sasse EC, Sasse AD, Brandalise S, et al. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev 2005; :CD004139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/53\">",
"      Gordijn MS, Gemke RJ, van Dalen EC, et al. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. Cochrane Database Syst Rev 2012; 5:CD008727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/54\">",
"      Bleyer WA. Central nervous system leukemia. Pediatr Clin North Am 1988; 35:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/55\">",
"      Evans AE, Gilbert ES, Zandstra R. The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A). Cancer 1970; 26:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/56\">",
"      Paolucci G, Vecchi V, Favre C, et al. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. Haematologica 2001; 86:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/57\">",
"      von der Weid N, Swiss Pediatric Oncology Group (SPOG). Late effects in long-term survivors of ALL in childhood: experiences from the SPOG late effects study. Swiss Med Wkly 2001; 131:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/58\">",
"      Hertzberg H, Huk WJ, Ueberall MA, et al. CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL--an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol 1997; 28:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/59\">",
"      Kingma A, Mooyaart EL, Kamps WA, et al. Magnetic resonance imaging of the brain and neuropsychological evaluation in children treated for acute lymphoblastic leukemia at a young age. Am J Pediatr Hematol Oncol 1993; 15:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/60\">",
"      Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/61\">",
"      Waber DP, Turek J, Catania L, et al. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol 2007; 25:4914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/62\">",
"      Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/63\">",
"      Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 2003; 21:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/64\">",
"      Hill FG, Richards S, Gibson B, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004; 124:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/65\">",
"      Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009; 10:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/66\">",
"      Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. J Clin Oncol 1998; 16:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/67\">",
"      Harris MB, Shuster JJ, Pullen DJ, et al. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study. J Clin Oncol 1998; 16:2840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/68\">",
"      Lauer SJ, Shuster JJ, Mahoney DH Jr, et al. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. Leukemia 2001; 15:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/69\">",
"      M&ouml;ricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111:4477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/70\">",
"      Ortega JJ, Ribera JM, Oriol A, et al. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL. Haematologica 2001; 86:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/71\">",
"      Lange BJ, Bostrom BC, Cherlow JM, et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2002; 99:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/72\">",
"      Hann I, Vora A, Richards S, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials. UK Medical Research Council's Working Party on Childhood Leukaemia. Leukemia 2000; 14:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/73\">",
"      Hutchinson RJ, Gaynon PS, Sather H, et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol 2003; 21:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/74\">",
"      Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111:2548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/75\">",
"      Sanders JE, Im HJ, Hoffmeister PA, et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 2005; 105:3749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/76\">",
"      Schrauder A, Reiter A, Gadner H, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 2006; 24:5742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/77\">",
"      Aric&ograve; M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010; 28:4755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/78\">",
"      Ribera JM, Ortega JJ, Oriol A, et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. J Clin Oncol 2007; 25:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/79\">",
"      Jones LK, Saha V. Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol 2005; 130:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/80\">",
"      Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006; 368:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/81\">",
"      Conter V, Valsecchi MG, Silvestri D, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet 2007; 369:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/82\">",
"      De Moerloose B, Suciu S, Bertrand Y, et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. Blood 2010; 116:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/83\">",
"      Lindemulder S, Albano E. Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics 2007; 120:e47.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Immunocompromised children. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.74.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/85\">",
"      Brodtman DH, Rosenthal DW, Redner A, et al. Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens. J Pediatr 2005; 146:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/86\">",
"      Nilsson A, De Milito A, Engstr&ouml;m P, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics 2002; 109:e91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/87\">",
"      Patel SR, Ort&iacute;n M, Cohen BJ, et al. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin Infect Dis 2007; 44:635.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Varicella zoster infections. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.725.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/89\">",
"      Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/90\">",
"      Pui CH, Dahl GV, Bowman WP, et al. Elective testicular biopsy during chemotherapy for childhood leukaemia is of no clinical value. Lancet 1985; 2:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/91\">",
"      Chessells JM, Veys P, Kempski H, et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 123:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/92\">",
"      Yang JJ, Bhojwani D, Yang W, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 2008; 112:4178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/93\">",
"      Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012; 120:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/94\">",
"      Roy A, Cargill A, Love S, et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Br J Haematol 2005; 130:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/95\">",
"      Quaranta BP, Halperin EC, Kurtzberg J, et al. The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation. Cancer 2004; 101:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/96\">",
"      O'Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br J Haematol 2011; 154:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/97\">",
"      Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood 2003; 101:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/98\">",
"      Einsiedel HG, von Stackelberg A, Hartmann R, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-M&uuml;nster Group 87. J Clin Oncol 2005; 23:7942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/99\">",
"      Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008; 22:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/100\">",
"      Beyermann B, Agthe AG, Adams HP, et al. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group. Blood 1996; 87:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/101\">",
"      Lawson SE, Harrison G, Richards S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol 2000; 108:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/102\">",
"      Belasco JB, Goldwein JW, Simms S, et al. Hypofractionated moderate dose radiation, intrathecal chemotherapy, and repetitive reinduction/reconsolidation systemic therapy for central nervous system relapse of acute lymphoblastic leukemia in children. Med Pediatr Oncol 2000; 34:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/103\">",
"      Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience. Cancer 1998; 82:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/104\">",
"      Rivera GK, Zhou Y, Hancock ML, et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 2005; 103:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/105\">",
"      Eapen M, Raetz E, Zhang MJ, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 2006; 107:4961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/106\">",
"      Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010; 376:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/107\">",
"      Freyer DR, Devidas M, La M, et al. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood 2011; 117:3010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?31/6/31850/abstract/108\">",
"      Dini G, Zecca M, Balduzzi A, et al. No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood 2011; 118:6683.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6245 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-9E6818F356-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31850=[""].join("\n");
var outline_f31_6_31850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Induction failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Tumor lysis syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5181929\">",
"      - HPA axis suppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CNS PREVENTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CONSOLIDATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PRIMARY CARE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Varicella vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Monitoring for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29267332\">",
"      RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29267339\">",
"      Survival after relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6245\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6245|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/35/574\" title=\"table 1\">",
"      Risk assignment childhood ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/29/11741\" title=\"table 2\">",
"      Platelet transfusion guidelines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=related_link\">",
"      Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17255?source=related_link\">",
"      Diagnosis of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=related_link\">",
"      Indications for red blood cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40649?source=related_link\">",
"      Overview of the outcome of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/40/24194?source=related_link\">",
"      Patient information: Leukemia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28058?source=related_link\">",
"      Pediatric palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37753?source=related_link\">",
"      Risk group stratification and prognosis for acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=related_link\">",
"      Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_6_31851="Frequency of laboratory tests following kidney transplantation";
var content_f31_6_31851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested frequency of laboratory tests following kidney transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basic chemistry panel (including eGFR)",
"       </td>",
"       <td>",
"        Every visit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete blood count",
"       </td>",
"       <td>",
"        Every visit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tacrolimus/cyclosporine/sirolimus level",
"       </td>",
"       <td>",
"        Every visit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinalysis/protein to creatinine ratio",
"       </td>",
"       <td>",
"        Every visit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HbA1C",
"       </td>",
"       <td>",
"        Every three months/or visit if less frequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipid profile",
"       </td>",
"       <td>",
"        Every three months/or visit if less frequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin D and PTH",
"       </td>",
"       <td>",
"        Immediately post-transplant and then every 6 to 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BK blood and/or BK urine",
"       </td>",
"       <td>",
"        Monthly for the first 6 months, and then at 9, 12, 18, and 24 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone density scan (optional)",
"       </td>",
"       <td>",
"        At three months and then every one to two years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Anil Chandraker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31851=[""].join("\n");
var outline_f31_6_31851=null;
var title_f31_6_31852="Smoking consequences among adolescents with chronic illnesses";
var content_f31_6_31852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Consequences of smoking among adolescents with chronic illnesses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Chronic illness",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential disease-specific health consequences",
"       </td>",
"       <td class=\"subtitle1\">",
"        References",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        Increased frequency and severity of exacerbations, medication use, hospitalization, risk of respiratory arrest.",
"       </td>",
"       <td>",
"        <p>",
"         Larsson L. Thorax. 1994; 50:260.",
"        </p>",
"        <p>",
"         LeSon S. J Asthma. 1995; 32:379.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"       <td>",
"        Increased frequency and severity of bacterial lung infection and hospitalization; accelerated decline in lung function, worse nutritional status.",
"       </td>",
"       <td>",
"        <p>",
"         Britto MT. Pediatrics. 1998; 101:250.",
"        </p>",
"        <p>",
"         Verma A. J R Soc Med. 2001; 94 (suppl 40):29.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Juvenile idiopathic (rheumatoid) arthritis",
"       </td>",
"       <td>",
"        Increased disease severity; increased risks for cardiovascular disease and premature death. Exacerbation of osteopenia.",
"       </td>",
"       <td>",
"        <p>",
"         Nash AA. Arthritis Care Res. 1998; 11:391.",
"        </p>",
"        <p>",
"         Gordon MM. Ann Rheum Dis. 2003; 61:66.",
"        </p>",
"        <p>",
"         French AR. J Rheumatol. 2002; 29:1065.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cancer",
"       </td>",
"       <td>",
"        Increased risks from several cancer treatments; respiratory infections when immunosuppressed; worse mucositis.",
"       </td>",
"       <td>",
"        <p>",
"         O'Driscoll BR. N Engl J Med. 1990; 323:378.",
"        </p>",
"        <p>",
"         Lipshultz SE. N Engl J Med. 1991; 324.",
"        </p>",
"        <p>",
"         Tyc VL. J Child Health Care. 2004; 8:288.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Sickle cell disease",
"       </td>",
"       <td>",
"        Increased risk of acute chest syndrome; possible increased risk of stroke.",
"       </td>",
"       <td>",
"        <p>",
"         Young RC Jr. J Natl Med Assoc. 1992; 84:267.",
"        </p>",
"        <p>",
"         Britto MT. Pediatrics. 1998; 101:250.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"       <td>",
"        Accelerated cardiovascular and peripheral vascular disease, including atherosclerosis, retinopathy, and nephropathy. Smoking increases the morbidity and mortality of type 1 diabetes by 50-75 percent.",
"       </td>",
"       <td>",
"        <p>",
"         Frey MA. J Adolesc Health. 1997; 20:38.",
"        </p>",
"        <p>",
"         Cundiff DK. MedGenMed. 2002; 4:2.",
"        </p>",
"        <p>",
"         Gay EC. Diabetes Care. 1992; 15:947.",
"        </p>",
"        <p>",
"         Karim R. Diabet Med 2005; 22:81.",
"        </p>",
"        <p>",
"         Hsu CC. Diabet Med 2010; 27:295.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tyc VL, Throckmorton-Belzer L. Pediatrics 2006; 118:e471, with additional sources as indicated in the table.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31852=[""].join("\n");
var outline_f31_6_31852=null;
var title_f31_6_31853="Contents: Geriatric surgery";
var content_f31_6_31853=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Geriatric surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Geriatric surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/16/32010\">",
"           Clinical features and diagnosis of abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/11/11450\">",
"           Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/61/11225\">",
"           Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/4/10314\">",
"           Preoperative medical evaluation of the healthy patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/11/30904\">",
"           Surgical and endovascular repair of ruptured abdominal aortic aneurysm",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-90F018F1C0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f31_6_31853=[""].join("\n");
var outline_f31_6_31853=null;
var title_f31_6_31854="Incidence of early onset GBS";
var content_f31_6_31854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Incidence of early-onset invasive group B streptococcal disease, stratified by race and term - Active Bacterial Core surveillance areas, 2000-2007",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 403px; background-image: url(data:image/gif;base64,R0lGODlhTQKTAdUAAP///wAAAP+ZMwCZZu7u7t3d3YiIiCIiIpmZmTMzM8Dm2WZmZkCzjIDMs0RERLu7uxEREf/mzXd3d//Mmf+zZszMzP/581VVVaqqqv/s2f+fQP/z5v+/gP+mTf/Gjf/Zs/+5c/+sWf/fwP/TptDs4+Dz7PD59lC5lqDZxpDTvLDf0HDGqSCmeRCfcDCsg2C/oICAgH+ZTD+ZWe/fw9+/hqC/k1CziV+ZUgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABNApMBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wFoPAQhGDxABEA/BzM3OdAUQEMVFEAYABhDP29zdYwQHBgfUQxUBQwEV3uvs7VIOEgDjRQgHQwcYRDAB/P3+/wADChxIsKDBgwgTKlzIsKHDhxAjSpxIsaLFixgzLqwjwYGQeUTq3cvn5Jy7kygVmZzj4N8CIuaEEEj3ZGXKmzj/2KwD0oFH/wDWsGmrmbOo0Tw76fT8eSzZMqJHo0p9kxRS1alYs4K56oir1q9gq3hlNDas2bNKyqpEy7YtE7WJ4Lqdq1XuIbt08x7FW4iv3mAaAwseTPhfWkt+//5KPNUr40CPFe+KvPdwJcqScWEu6hhxZpSbc3a+/PlkaJyjKZ0uHWt1ytSTXLN2Jdu0ZdWz2dV2B1vS7typfuu+HRu4N+FKyQkJcM3JsKdGEPBTvqZ3JOTGSWFHUgCgvTAgjYSnMu3JgpdfrFvNzm27kmFlxhORH2VmAfPovah/5J79p/5IwAcAAS0F4AAB3VVwwDgQJJCMBAcEcMB9Q2AwVFAGJCBPgT+NY/9APwYQyM+BRHRXQHcFXlNgAMPwkwABACyQQIQTtmhgBQ4GkJ8V+3Xl3zMAHiGgA80lYEB3C8CIQHkOHLDMAfEMMVMFw2h4QTwHHNhdPvP0VGRzQpjYXTzSIRgAhfdcI6M6UMaI3gUvVXBBFj02EuSPmlSlwAB89unnn4AGyud7JrlkohAiYfPTeUUYKYEEEFQAAZfUdFkMSC6VeOahYp4JQAELgOimEIwyKtQCYF5RJ1l4NqOnoLDG2iehy5EUpqcAJGrAojtic8EBcl4AAYwgWSoPNQHYWkSn9zELwAUJ3EfkqKOaCkAFCzQJo6rE+dYqM3cWMeSL2ByJq668FmH/joYYBDDnsR9dWoyRQjhArgGpOutsAvEoqCZ6jHZUbzHDbMtjt9d9CxgcAhZQYAIPHJrrd7uS2itQ1xAQFLzwziMdcw67CN2nm3rqbFMz/mvxtcgQKSoWqy4SrsK4SRbzWjT7MjMwN8eVs86Z9YzIzj/zFzTC6xU92dFJEH2G00rLzDQSUJdRddRDT33E1UOEyk+q9foz8hJcY92X1kaUDUAC6pRZxLRSqG22IHLbIrQaGRoBdxR1z60T2kXI/bE6b79ckt92A05E30saTA9NhyNOS99VyEffEdYW8WESXqPZxt1qsNj0yPsQJPnkbXT3z3dXWE4dEpk7YY7nS1yu/wXoZDzgwH3ZwOjTp9EK5TjZp8/itIBauN5E7E1gwHoTttOJtBshS/jU7yJaDwXlxeNxvEnZa5nOgks6CAGEEtJ+QI4dFrMiNRK4CGqcGyNqD4pfA9CPAzaSm+WI2ADRkqZzu+n5qHuw+F69voQkJTHJSfKI0j08Eg15hUQb4rjPBR5wHklRRyRjylUACJCo+VwjS2ailBDKgwAJcqtpnkHgK171pyLsqYZEuKGfaKU/fyxAYuha2Xyowah5ZKgfANhbjBJQHnrcz2RnShSoRFUsCyYxAQt4nVgMaCcZzvAIOpxVDgFlQzImQUDJ0hSFgkite1DjSscyxzXgo8QFNP/oJyF5YrOi+B1oSeuElbJirmT0LphxkVVebIUCrwgjfAGRYukyIcuehAAL3SdU2JjQsziYpAP0CoRQLECi+HWtcHBsHvQqANuwoSHpwZA0iWTFIqsHsUcKoWJt/AgymBOvJI7IJBeQH6MK4Mk8kmyPovwOykxZRREyJ5jacyXVYhhLVXBPFrgjxDWrSRXFoYOa3DzFNhN4SKmFExXj/OIra3ZOU6STNuXEWTtL8U5FxtNn86SnN5cDznyGop6yvGfW/DkKgK4im4MwKEG3sk/99XOhnVBocAR6F4j+8xQSu6VdNncEAjjoeVtAKN0sCgqi+QNsRyihGDKqRiuI4wn/LCXeOotDUk+YdBnDIFwSVBqGmN6KdlGQwMWS4NOZpu2hNcXETeN1ng8hAEf8iIc/coUMFgJLR+sbETTBJoE5mWMZV8IfL0WyogdANQAunBhVc/QAG+GrHy8Rq4r68YABEmOaRk1YUjmxVOmAKgHF0NgyolFXZWrSQiTcGAqHMSe3VQiDaAUKBkJYJlDeR7CfUoYxl1QMGeWSZBWg7AglxsK0fjOvSdtrno4QAQG49rWwja1sZ+vapvGjPKay0XR09Y9kunE5g8WVTNJhpEiNNpSWBYBu7zoEkSRKJLktK6dKRiF7ZRG1p2WnapXKWtp697uvHR0RcjtCY7LSib/V/19waXclbUDgAhRErh6VW96U2uO59jDVe4E73RMJFwGExKuAabpd7rpBdF1Dj8ZeQoANIpa+xcCRWnup3mNqLrLxu0Z/RTKTZSx4QBvc7Hegy+A0Sidioeww8NSRt61R1BASLTAVlprgITyAfQXwKD+Ewo+XlBBT61WX6HJqYRMlymttxbGI7UetDxmIRf2NET8wAE0Iuhi7V9gWBob3ORkbWDEiTUI2QgYBoFbHy5eIsThf3IQEXMAcB4DAUEOHZqTOJcxI4Jd0DCCBVnazztrVC56P8KuWYKDPcVAzoJugaH1iuQrtktDa5pyGRi+azVkZ9BEOfSIJ6PTAl/aWzf8w3QQCmJrLbLB0qK8MZlIrQUH+MO0SvMZLcVV1bDJd9QFb/WgqrCiqUVilY4eAoaFETtddHHWvp9CkHJu6Ci0ux0ogx2hk7/ovmpYSAZx3alQzYXDo/Yiycm1teW6CpTzljnDfhsci6BikIXW1EWYSEFk3oXHmlYeySjeQciPyc4bbKbytgO6BG6GoS3ipExA+4KNqgd4AsTejRxaTAVH7Lf425+dwenH7cqHgTWB4EoQK03VjfNlQ6Ha3o6A73g0riT8p9vYybu7qPGUcTSXGWaWKxAFa1RwLyKqBtrqsAOToGiLpH4zCdygZea5UM0qfW99HshT5kh8PiJ+EPh3/OHkjwQD5eRQUqmfl3yn31jOn+UA3LsK/BlazhE3UAw47rCU1Z7HuEqHjunONdvlWkr9TpYlkNDyosykesVsSych03PvMDgAS0CI/UZ7yPp/as3BQtb+r0trYFqHzsP28bG2bjM6iZ7kI4K0//s4x0bFUYuMAIa2vgeCqk6sIpQLYS0x1xB3391Aac8ACuN51yjsh0v9od5fVXlEjgD68RHh+baM/eqqNjLyO05WfmUxh16+btBgQiR+TSHvodMdBuM79yhglR/oWmbpDAHv9HN7wKyC/H8BKNPObz/YaD0jOIPYADzYMEaYhP4YsQTYECUJVJGQPpOQvMAc8JpIN/1ynftXyEpYkZe+XY6KDABfgOxKXbVIiDqc2B5pXbjQmRMqFYzp2DtnQYxPWegl4K2iXdMiQMsAzIodCgeO1e7pHLRxyDlHmNb0XPPW3OF7wId62fPunTQ3lGtHgbEtYaU14Nsp2hFegdf0gcWhwgtbmhf/hdUeghcCWeVXohFfIalygcnIAhrrmhhElhkSwLWyof2c4UmlIf1gwE4/yD1z4NHeIh7yGhVPAh2QYWWYYiIAAh3wlh1IiEytnh4roB4y4CSIoLhhAfEw4iXxQiatlfE8AayMyhYDIiX3giZlwiWGzPhFCaV1oiqdYGLI4i7ToEI5IBAngZ9AiibCYcf+nYWr1cGpil4i96ItbAHF+yIvF+IXHKBB/aAaouIxf8Ysq92zKKI2rFo3RiI1YoY3cyIyw9I3ZaGfi6GWygQD2giOSR4XlGGqu8TEj5ACFBGrteGmukYtKiGjEWI91do8S0C4Ntn2byI/m6AV21BLBhFJnRpD96AUtaHSkCI0M2ZAOyWch0oYTiWauYQAXMG5P0GC39Tq/hmugmJHt5BpaFw6aqASqpA7xozcKeXImuV2ywUERUmtSMHcwOQXbOJPtUBsFIA6IKAU/pDcBJ5M+mVSugQErgg9TYAAriSgXx28CkZSqhZLJEGLM5pFpQ5KEaJX59I4XOQWqBDaBFzz/vQMVYElSvwiJJQgFqBeB2WNlx7aWEBUahpiM+2iXBIWXaHWIz2g1fGlRbTkgkbiXgzlP1FiNGJmYfdmM9XaNjhlOfhmZiDmZ3LSYdXiZmBlL3tiZJ0mOoIlAnzmamemQGJCaEVmKpvkjGQACFnAwXEBrMCiZrTkbI+BaEyCbWuBkuXh0tnmbnzEBrgWbvJkFM4ImxCSQqSac2bEBGjAChrQFudgozLmQzilDpxEq/PIoDuKKrJmd3fOLOdIPt/dn4vkXEdABGaAfXnBoj8KVzZmeekGcAsAB7tkF26aaJkifb2ABsVkLFkABrsUBAcoFq0GbOtKY/skGIdABIkAL/9ApABrwAQy1Bb6Zi/nDmQ1aBvZJARswCyEQAu15oVqQnAq4PsHZoWNgAfapAbsZCwAqBqdRnbh4nXTGomywAQQqABFgFNtpdI/SZwvKoTq6Ba95oEQgAjGqCh5goeG5h+XpIqtJBj3JBx5gnK3yAbo5CxsQAhSqpGOwlEMqn9i5DhGgpQCwAa5VoXjCAcUppkgwoD8aCiKgARQaoVGaBfu5Zf25DhsAAgVKBBkApgIAos9pqE3KBB5QoHKaCXAqACEQoq84m5myor+wAZF6n5RKBBOApx2QHRmgARpQp05gAY1KodLZCY26qHvqUi6ioThJj9xgnyDQqUbAo6tqHP8RgKtPUKiu5QGeYKrseKKaFCYqaqS/YAEgQKz5NAId8KjOUKMCaaPoGQzSGgUZ4KxusQElOgsZ4KoDeQXcOaTfiam3sJ74iQVgqqZtcachkK1YMALf2ggjgKd6eq1S+g/nSau9EAE9qgHy6gSp6qZtYZ/xCgYZEKwDGwjM6loU0LCC2QXw+Y9SAJKlZwxop5a7YAGbOgES2wTAeqghmxMPe59icLIGiwgZ0AFdyqBy0JKQlxQyx7G6YAEuywG+mgWfGgJoEalQOgbrWZyJIAICwJ50IBz0MgU6CRPTFpV6uAu9GgbeihYbgLRn8Km7eggfULISuYYqN5RRUJT55pT/dVkL+cp8O8sLp3GIZRgFUBkdrGO2QkCVAXELH+Cy3HoG0Lq3fpMBa3sHXbsHp+FkegkFDsCVFTclNgsLEWCoHeC3ZWCo7ooShVqvcUCgIKsHA4qyerAa0NJtYssEZcluK3QN2ZB2shCpMOq1XoCqbRq0J/EBeLquc9CjEIoHEYCn0Um4XQB2uBiTAfIP7sMUG3u2r8ClmxsHI4u56xCplRsHIuCyJFsHCOu8dlCashC4bjAB4toNFqCoeeCikloHE2qgpyiao+CiaXs6IaAB7XsHVVsHIiC7vhuOqXCvRysIqOq6tzC/gsC96KS+n5C3rpW7gQCnkYtAtPu9YgDA/4K4BQVgpuM6Cgt7tPb7B0MrANGbCxsQv4MQqQtcBvDqvzDbm/X1p6gAAstLCLBLoZJLC7urAdgrCLTrqGOQqgmbUF4QhW+prH9RqALLC7kpqQIMCC8cw1fwpcEKY14AmOhqCR4bqpFwxLBwsujLCBmwtV4gqPDLf1sAxUBMCS6KpwKQwZFgwqJQxFzsCoFqxZ34BZupr5qgv4eqxIzQWh6gxqAAAjXsCDjbxiX1BejINoAVxZKgwGgsCfY5wqdTxBTwx0sAxxGsBfBIIPNYwZiwAYtMCRvcwVhjx3sMBR5Lw9d2okYyQvpIx5OwAXwMyKnayaHQsrJMxoLquSJrqP+1zMNdwC8AuYtjrAiaKgAO3AkZIKypcMM++wmPG7I3XKpG0wUH6S6zqsmN8MICgMxelKoRCwtcWr3RvIbl2a/WvAh3CrGSPAockM6W0KPabAoTAMIAEALFjE/6aZFVaqWUAJ0UgMdrzLCf4AErawpseqiU/G9dIIBQW6yGkAFMygEUAKNFwM6kcLKOzAkHzQn2ScyvXMlZIIoGks80GggbMLVE0KOv9c4yTL31rDQ82sRp5gUtsT7IEJj6zAcfQAGGistCMAIUMAEjEAEU3QqwO9SJYAGC3ArTu8wE/A6tBA44ytBvEAFM6gEqnaoQq9LM0NGAsLsCIM+sMKMxTbH/B3BqWCTSJtq9sUUBnycCEcDVuGDUgVDEJOpFWAkQUf21Y7ABIzABIECgbE0EudkBFOABEyDX3QCddb0IHovDdv3EAZHXE4ukEcDFRRx6bOHV2QzX0utaSX06slGNaJ0eWZABFEC90zcErzkBH/DWc3GyAsDFgDsIE+DPc6O9SmABEfABfh3YQwB6GkABtssaQ+uqAUsBFADW5YjbSCB9AoCruo3YeuGrWP2yQ6DTwu29Gc0FYq2YTQ0Ah/rTQc3ZrFHSIoC5qG3dQmDY8SzUChsCw31OzL1dul3ZE7DORSBbXNzark0F56wB2+0355iOhxzMaMakE4Dc0EwEsYW1/0NwxAhL3jTzjv2AyYiccRC90876WsjtAbgaqVot316Aj6os2XpdjBkgpmb8WsR6p7ucSP74yyY+2fVY0hHQwkIg4UXjGtOckFJAWEcwko17pD/jGg9JzkyAZEEuvLdI5IKGmhbpp3FDkko05E6uMDwuOh825UF+lHYLEFceNffoZ9a6PV4plQuNhGG+4yM+tzPelWRz5lG75t+ykQbSEdVcEtBxli6Xz1dK5+7kkOOM1rRZLx4xl3I+54D+I6GNzye86IwOBofJypCeHa4B0qM7n5WOJ67xa5l+ppvOHp0+IT9M6aE+G0tZ1qXur6duHHe9hRfe6nnx6m/L6rKO6v9yPOm2fuulMd+83lBVUMjqGOu/zhYUzg8WbuDFbuwjnsoEsMq7vuzYNuL/OELAbOrSThc8DgEImeegnu3Trp+DTuzgPo1ga2pgN5bKXu7m/nDOSO7s3o2QGXHwHu9SQY2EZ2p0G+32jhb3yDoJoHya3u935gXBBA8HX+8Ezxk9fJPJkOY0vvDMXpEScCSPLvFmUZhzzO8YXxfN2IexpvAdDxofL8bYPvKNsYZuaY3rjvI3YeSTNSBSfvIuXxnSrOUA2PI1bxu9TOZvPqY7Hxb/fg8/P9JB3+5c8CHw0BJMzh2apbFOobpHL+/ibp6EjnVHULPIO/U2f8+oMtrAZQT/Fac/ED95XJ/yXYDpNh04uPZjFFx8Z3/vMn24Zi63I6EPBRH3aM8FzbbqNYFri9txTa73bPueqs7yfLPnMYe6xlZthN/1YUz3yzNVEXh2UW/lj8/zXGDyHJ/5w+GQul7Onr8OpzHBRRDzOj/6PLP5IyS6a2/0qv8arE/vqR/7vdC2lknztj+trB+2rx8Gf777dVD644b6ui/8C4O/yH8c3738QKP8zr8Nvh79ZWABTCoCAe7E0E/9YpABH8AB6X20IBDUgaZX3B8GNw4CKw6xEC1bIfCk2R/H2y8IJqAADbACDOACA1ACRQAEJMCQWDQekUnlktl0PqFR6ZRatV6x/9mkReShCMBgDWgSMWZGnE5YTClbtHFsQF63D+l3PZGkSJWKTAYGCRWKSAZaGBoM9xwfISMlJymhMj7U2AQ6OD4ynCwiJig0NEM4Rj4r7fJWXQFaX6MYWAgHGokYVhpUcIlUWmwHZImLjY82Rso2jpuNREFK2Sg8ROCsLjlCNAXcrJ2hYsH1xIkVFBoaGFx8AQgVTwClSlBeXFyMSFCExvv9o7hkMkVGhJl/kLh40TSmzB5o0sJ0ADHC4EEi5SzOcVVCgTwiwWw1yMdPz4pBLU40IJmRZTNR29iA4ECK2yY3FK+1nJJtDRtOnipt6PJFE7UPzP5h1DlF6Z0UtAiJLP+ygsELXgpMVEJxAuSAE0vBBv0QjU0IDxWHhFJGoedCChyWhT3ysGi1nMUijADRVgwZtMeaym0SWEqfFOpQGGHwjkFifyRSvHBMZIVkj4IxA+zC9+ddJhFETABBlFsIMh/++ktIum/DKib8UFWhh8uo0p1UESOcGcluJCUuA1hs64URFOcyd2Vxoh1v50My2I6ZSssGUV4g+qSG8xhPTT9zWxke1UgDFMGxZIMZRoM3z5J8P8fzpARVF4O+TmVR1fxK+ejGa06+sDYYKzuzREAogg9G4WsauCII7xG6prFrChJUaOCEyYY4YQAXUuooEEJYWEGFrOQIRbTsNkEltT3/4pMvvhKEWWFAKiBDcQgaXTARvRub6WI9ATToBKlXMghttJoEMG0C1FIcaiG/rGhAGAaM0BEJE9Sxxb86CvRgSDCoEeHIO2J8LsargJRDAWFY0LJNJEdgrRvq/LFuAuxq6mC7CN5bwjufcIMCthRWsLEIKxVZYZ8qVKDKiBIY0SOvvb6jso40neN0TjlMyHCxFrIU8NM6LMAkuw4sBCsUBikYM4y3JhBBQgAonLVVKFCohcRJ5awjBUJOSOHL6kKzs0kPgNLo1CPim8BPD8q49VkcyxtElxOvzSICMdkY4yggk5xgJiZDoMZOhl48ooQMiytChUFA5KUSBV7w9cNI/9AQKIx2w+m2iPiUtYnaCM4UWIoU9B0AS4WjQAOEoiaw9lPrRuDzu0KdIGG8QbI8dpUSUijWCBXO20NFUgKNwtPMYsxAlJlYDCPdCShKGGIl3l3BBamISMHYnYlI1d8WvyEaiQVrbXkIP4AeApFEdEkhWIvuG6BEbg96GTOvhwDNXJpqujlnpZ/Qd5EfgXwp3Il0RttQqAoxAqvMuiQkBYvAlqvvpUOjGd3TAJXbiJL15fDGZMiy2TXDl1Agw3RO8I+Qetl2LlIX/Ku0mb/BAp2JV0UrmEzCne6WnheC00XkjALijIOkIU9HQwYYsFyYdnoxfGqvhtZtZ9GlIH1JJv8pIBxyAOYdpMTXwYluzIkslk9OdXCvZbYiuhpk7yJeWCSdP5afNF9biiGeEgcCaD+ABwI+hvRYmWwProIyCyWC/fdXZoL/cca/CMygBjZA3z8K1DgwmAVgLYGNiIpwAroN4HtEyBp5ioCCdBwHguWbR8kexoeUwUcuDjAAFdRnB4yNQlZtuF8D4yAzATIIgP+jwA1x6CAm7XCHfsJh8mr4v4IIMG5ZSAhfivSB1B3jgX5ox8cGEDXhCKOCQ0BBL5DjwUqYRGsmupocUigJE6IQLCukX03ac7DcWEeAogjiTH7YQh7OcRo/pFUN4YhDOdKRjnakRhBR00YioMFOFMD/E0ugKMXx4E5xfYCeFmWBgo/lB0YldN8J45cZme2JLXz0ZA/tSIYgDpF/1buCDCMgAxncIAatpIEN7VizT84RQQfxw4YU4zDcvaAdX4TkUjZXRQAcB4yZQUAAKlAEGLiPmcyc0ya90Jb22JFaNaSIIB24FUIoTglsFGAQSxdH9hjpICm4oMN+qUWQFOuRg+HN+zKZzsyYYCtyaqf1Oue8FwRPnoYrwfnqZoUw7sEBDgBAARJQAAAYAAIEiGc/BzSv583plrVgQT7uBlFIkowrvnTCQPVQUAAQgH0BOAD8HqpR56DAFiW6EUttEUKVztRZCouPE+9JU1fQ00Nekcu7/9QxKRbs01Q6NeoTQJqUJ7zAFvBoQAqyeFRi0LMdj/KHCU7QsKJKlasuG94TtjJBYWhLfFHtaiUE0cWc7oEEciLEtjx6VrkqIan+eBlHNBi+ho3VBbq4SlznWoUS9NR5a80CUIejOBUYNrCNnQ/E1MeRDNlnrLbo6y6OkznHOoGniajEOVvAzc2O9qNffQRsJou7ypKIP5kl7RNM4J9IMfYIkNmnEcLno9fuNqXPqisTzpEO1a6WaimBKm0D29OJRkGSMeXtcwVqWmcY5nbdE4YiyrrVwKqAsANQ1JbyqbWUIBe6z/3tOM6rBerqlbi6TMc5AKvTzm6PCH6wh2eL8P8uzZaXv3SV7k8VkFextnc/uDPwgW2XYNtB9RwNdvB+T/Umy/aXwjUVWHrRKrkGULa9Hfbwh8l64AOnRMEcjG8xTLAcz1WYxWSELNr64GAHT07BtgufiA9sXRCDGHckxmKLgaym/5a3iTI+hwYVLEEorha7VrmKdoMcZeG9WMpR4AjUsHdO4hZ4F4xQAHmrHGYX21TMWrjyYagy4NVy+anngHCZ4bwEDH8uzo6IcTrSvNfV9lV8DH5znaU8Z8AA2hXnmNyNdVzZHteYg0Y+B5gBPeMEpzl7fMWxXxnt6D9PmcyEBoehKTfcHY+aapdedI0X7OgGQ/pZRUZyqA2caFL/z3rH2BUxiWus6mJS2dMseeCrbadkU+uZ1sUmrq1NjeoEq7rBlLjyOQ5jOxEb+3IIXvaqj6BqZQs7x9QGMZTlPOReE+3ZjgZ2jW88bG+ve7WmNjCqKa3mWY84wQx2s0XK3eBz4/nS5zxxEgRtjICP24P5ljGN4e3udbAbxMh2cjqwCF/+DpzTBLd4FopsZIRfu9meprgsPn5xkYs85K4o+chR7nFxp5zlLc/CySsBc5fPPMgyn4TNaZ7z/uI8EjzX+c936/NHCB3oRW8s0StpdKUDHenkWPrTc950NEGd6i2XehIeAIEAQAClSK3610d+dSRA4IQM9SrY0T5usRuh/wKtQGZv0x73MK+9CAg4ABEOgAG4y53vQKY7EeyOd717ve+FD3RY2j4EArydCMts5uMhH3nJT57ylbf85TGfec1vnvOd9/znQR960Y+e9KU3/elRP3q5kH2hEHB66L4Wlr8bYfaPhb3slZb1rXd9U7gXTO1rfxG/Dd/3rwV+7G9P/OQvJfjBZ8nxf1986euk+conLfSt3xLnwyL72u++Y7E//ecjf/nU//7RxW/+8jP//Hxr/1zDv/6MbL/66Z8/b+PPfvl73/7u77/hATAABXAACbAADfAAETABFXABGbABG9Du2scBHAoASsqghqACiQADKaECEqB9EiCZFsoDFf8qBAMgoYgAAwaOAC6gfSAAAYZA97juBbUuBlWQBV2QEgzAfSRgCBCqfTCpBwMAkxiqfS6gEjjQA0EwB0twBJXQBIkgB0dQEmpw624QBlHKCi+QmXgPEpQwAHbwoDowCHkwDDEJACAw4M5QArMwACyQAiNwDd3nlxbghAqA9QzgAAiAAA6g7PBQD/kwD/eQEhDgAhwqAQyq7ZLpAooQEQFAEYfgANpnFRAqmSQgD+zQ9QDgEsGQEgPOAVwQBeHHERlRFN/uAlywAiBg8CRhEAvxEEtxEV/xBLUuCiNhEgGgEodAEzOx7DBxjFzBEwEAFBsRFhORGIOxBV1hDg/KDvv/MBDvEBDLcAgWoAj7CRgvQAiL8BqHwACyERtfwQAWYKEsMOvEUQaJ4AFK7gHuLvHwoALYERZA8AXv7hUCQKFikAJP6B59UQZpEQfD0QDG0fUA0hwBoO1QsB8nQR0L0u3ckSHxUeDsEaXGSB9PKAGi8RWs0Ru1caGokQfrsZ8qAJMO4AYRIAEAYCSHoCRPkiRNchVUUBrD8aACgAAWICYLYCZfsOQWQKEC7xExoCdPUhUBYCe/EX5ucgQXQAKOUhq/8CbF0BVecihtciZr0iMJoADybimTkSfnMSiBMu/c0AeLUiaRUik/ciglYPEgsQQn0AhFkiVXMiVbcgguICbT/6kA7BIlzdAk9VIl+3IuKYEQYdIqq1ImJxAdZcEAQPArf7IrwXIb47ESftIjy1Irk7IIUHELJUEwpZIwp5IALJIsXUExU9IxG1Pw6o7xKGEyRRMtLdMs9Q40v5AS8BLv4PIvz/Esf+kB2rARMUkCunEIgNM3hbMjJQGhonAgj7EclzMnMVIV2XHxGlLxGM8BhBIHZzMTUSo07zE0i2Afj9MJmRMDBNICyRMWmukGJ8E6iSA6kck9IxMWNPMRDCA7uzMft/OEGE85E7I3N3I4/7MjHcAuIekZi+AZ/XChmvEPEzQhISAyR9EYHdE5KwGhLlIXNdFCMdI4h3Ehi9FDAf8gAeAHHedzD7IOQmMxQotAK8PzQnkxF18UOVuvLSPBATiUFD+UEUWqQSXBQJ9wQRUUGvlRnkqqfeZRA8OyDZG0R5tJoZqQCUXwEd2nNyEBHZnJBbEQALDQSt1HPXuOmcIRCH+QDKXxkiqhC9vHSaOUBMWzNSWBS9sHS2fwCud0pErqpGIOTMFQLPf0KYGQQyGhSE1qDZX0DR/xIh0wURV1URm1UR31USE1UiV1Uim1Ui31UjE1UzV1Uzm1Uz31U0E1VEV1VEm1VE31VFE1VVV1VVm1VV31VWHVVK1U79ouALw0VnFVDkuwEdkwV301nQhA6xZg6xRqCsUQBXVwpNqXpxKz81ed9Tm68AvZB34gsev00FYXL1mfdVufowPn0SmZyQAIoBIvKVvjk1vRVS4qkRqdkhbZpwg7UFzb51zTtV5bYl2JoAOp8QIwIF6vVV5V014FliXwVfGGNQILgDxNChIBll4H9mEhNmIldmIptmIt9mIxNmM1dmM5tmM99mNBNmRFdmRJtmRN9mRRNmVVdmVZ1gCDAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: the Centers for Disease Control and Prevention. Trends in perinatal group B streptococcal disease - United States, 2000-2006. MMWR 2009; 58:109.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31854=[""].join("\n");
var outline_f31_6_31854=null;
var title_f31_6_31855="rTPO to transplant donor";
var content_f31_6_31855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Benefit of recombinant TPO to murine transplant donors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 353px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mice were treated with lethal irradiation followed by the transplantation of 1 x 10",
"    <sup>",
"     5",
"    </sup>",
"    bone marrow cells and the recovery of the blood counts followed. Top panel: The administration of various doses of saline or thrombopoietin (TPO) after transplantation had no effect on platelet recovery. Bottom panel: Accelerated platelet recovery occurred when mice were transplanted with bone marrow from TPO-treated donors; the response was similar in recipients treated after transplantation with saline or TPO. Recipients of marrow from TPO-treated donors also had accelerated recovery of the red cell counts (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fibbe WE, Heemskerk DP, Laterveer L, et al. Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 1995; 86:3308.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_6_31855=[""].join("\n");
var outline_f31_6_31855=null;
